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Introduction 
The pharmacological treatment of many pathological states often requires the 
cooperation of different and complementary pharmacodynamic mechanisms. In 
the clinical practice, this is frequently achieved through the administration of  
“cocktails”, composed by more drugs possessing different mechanisms of action. 
In the last years, the “one-drug-one-target” paradigm has been shelved and 
numerous multi-target drugs have been projected and synthesised (Fig. 1). Such 
compounds share two (or more) desired pharmacodynamic properties, ensured by 
the presence of overlapping or conjugated pharmacophores.  
Compared with a pharmacological “cocktail”, the use of only one multi-target 
drug presents some advantages, such as an easier prediction of 
pharmacokinetic/pharmacodynamic relationships and an improved compliance by 
the patient, due to the administration of a single medicine (Morphy et al., 2004). 
The release of nitric oxide (NO) is the mechanism of action accounting for the 
pharmacological features and clinical applications of drugs, such as the “old” 
vasodilators nitrites and nitrates, because of the fundamental roles played by this 
small molecule in the cardiovascular system. More recently, the NO-releasing 
ability has been individuated as an interesting property to be added to molecules 
already possessing another pharmacodynamic pattern. 
This strategy led to the development of important multi-target drugs, interesting 
pharmacodynamic hybrids joining to a “native” mechanism of action a NO-donor 
property, addressed to reduce possible side-effects (for example, the gastrotoxicity 
of aspirin) or improve the therapeutic impact (e.g., the increase of antiplatelet 
activity of aspirin, again). 
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Figure 1.  Theoretical template for the synthesis of a pharmacodynamic hybrid. A NO-releasing 
function is generally bound to a “native” drug, directly or often through a linker moiety. 
 
This PhD work focuses on the fundamental biological properties of NO at the 
cardiovascular level, on the chemical features of the most commonly used NO-
donor moieties involved in the mechanisms ensuring the release of NO, and on the 
main classes of multi-target drugs, showing the conjugation of a NO-donor group 
to a “native” molecule acting at the cardiovascular level. 
 
Endothelial Nitric Oxide 
The vascular endothelium plays a fundamental role in the regulation of several 
aspects of blood circulation. Following both mechanical and chemical stimuli, it 
biosynthesises and releases many endogenous compounds, which control and 
modulate the tone of vascular smooth muscle cells, their proliferation and several 
steps involved in the process of emostasis. In many pathological states, 
endothelial disfunction is known to account for several aspects involved in the 
pathogenesis of cardiovascular disorders (Noll and Lüscher, 1998). Among the 
heterogeneous compounds produced by endothelial cells, the most relevant one is 
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probably a small molecule, originally described as endothelium-derived relaxing 
factor (EDRF)  (Furchgott and Zawadzki, 1980) identified as nitric oxide (Palmer 
et al., 1987; Ignarro et al., 1987; Myers et al., 1990). In the endothelial cell, NO is 
biosynthesised by the endothelial Ca2+-dependent constitutive enzyme NO-
synthase (e-NOS) from L-arginine (Fig. 2) (Palmer et al., 1988). 
 
 
 
 
 
Figure 2. Biosynthesis of nitric oxide by NOS from L-arginine. 
Besides the well-known endogenous and exogenous compounds (such as 
acetylcholine, bradykinin, calcium ionophore A23187, etc.) accounting for a 
chemical stimulation of the release of endothelial NO, blood flow and shear stress 
are the mechanical physiological triggers for the production and release of 
endothelial NO (Pohl et al., 1986; Rubanyi et al., 1986) and an endothelium-
mediated vasorelaxing effect induced by blood flow has been demonstrated in 
animal and human vessels (Hintze and Vatner, 1984; Hull et al., 1986; Pohl et al., 
1986; Miller and Vanhoutte, 1988; Drexler et al., 1989). 
Conversely, the inhibition of eNOS causes vasocontractile effects (Joannides et 
al., 1995; Reesrees et al., 1990; Yang et al., 1991; Tschudi et al., 1991) and 
determines a significant reduction of perfusion flow in isolated perfused tissues 
(Meyer et al., 1993). This endothelium-mediated vasorelaxing effect is principally 
due to the NO-induced activation of cytosolic guanylate cyclase in the vascular 
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smooth muscle cell, with a consequent raise of intracellular concentration of 
cGMP (Rapoport et al., 1983; Alonso and Radomski, 2003) (Fig. 3). Besides, 
other vasorelaxing mechanisms, such as a direct activation of muscular potassium 
channels by NO (Bolotina et al., 1994), have been described. 
 
Figure 3. Nitric oxide pathway in vascular and endothelial district. 
To remark the fundamental role played by the vasorelaxing effect of endothelial 
NO in the regulation of blood pressure within the physiological range, it is 
noteworthy that often most cardiovascular diseases are associated with an 
impairment of the vasodilator function of endothelium (Vanhoutte, 1989; 
Mombouli and Vanhoutte, 1999; Vanhoutte and Boulanger, 1995). Indeed, the 
NO-dependent vasorelaxing effects of acetylcholine are decreased in patient 
affected by essential hypertension, as well as in aged humans (Panza et al., 1990; 
Cardillo and Panza, 1998; Taddei et al., 1995; Taddei et al., 1997). Furthermore, 
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specific physiological functions of particular vascular districts, such as the corpus 
cavernosum, are ensured by NO, whose release induced by NANC (non-
adrenergic non-cholinergic) neural influence, with the consequent vasorelaxing 
effects, is a key-step involved in penis erection (Rajfer et al., 1992). Besides its 
fundamental vasorelaxing effect, NO controls an another important aspect of 
cardiovascular system: the platelet function. In particular, NO, produced by the 
endothelial cells but also by the platelet themselves, reduces the platelet adhesion 
and aggregation (Radomski et al., 1990; Azuma et al., 1986; Furlong et al., 1987; 
Radomski et al., 1987). 
NO is also involved in the regulation of the modelling of the vascular structure, 
through both direct and indirect mechanisms. Indeed, the platelet adhesion on the 
site of an endothelial lesion determines the proliferation of vascular smooth 
muscle cells, due to the release of platelet-derived factors (Ross, 1993). Therefore, 
the anti-platelet function of NO represents per se an indirect anti-proliferative 
function. Furthermore, NO inhibits the biosynthesis of MCP-1 (monocytes 
chemoattractive protein) and, consequently the adhesion of monocytes to the 
vascular wall, where they could release proliferative factors and cytokines 
(Hannan et al., 1988). More recently, a possible role of NO in the process of 
“ischemic preconditioning” has been extensively debated. Although, to date, the 
different experimental approaches on different animal species do not allow a 
consistent unitary theory on the exact role played by endogenous NO and on the 
specific contributes of the different isoforms of NO synthase (Schulz et al., 2004; 
Lochner et al., 2000), there are clear and unequivocal evidences that the 
administration of exogenous NO-donors determines a significant reduction of the 
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myocardial damage in ischemia-injured hearts from different animal species (Qin 
et al., 2004; Masini et al., 1999; Nakano et al., 2000; Schlack et al., 1995; Pabla et 
al., 1995). This experimental evidence lets us foresee a further intriguing positive 
aspect for a rationale use of NO-releasing molecules as potential anti-ischemic 
drugs. 
 
NO-donor drugs 
The prototypical class of NO-releasing derivatives is represented by organic 
nitrates and nitrites, such as glyceryl trinitrate, isosorbide dinitrate or 5-
mononitrate and amyl nitrite, able to release NO after a metabolic bio-
transformation, or other molecules able to release spontaneously NO with a 
temperature dependent mechanism, such as sodium nitroprusside (Fig. 4). 
O
O
NO2
O NO2
NO2
Glyceryl trinitrate
O
O
H
H
O
H
O
O2N
NO2Isosorbide dinitrate
O
O
H
H
O
H
O
H
NO2
Isosorbide 5-mononitrate
O
NO
Amyl nitrite
Fe2+
CN
NO
CNNC
CNNC
Sodium nitroprusside
2-
2 Na+
 
Figure 4. Chemical structures of the “classical” NO-donors glyceryl trinitrate, isosorbide 
dinitrate, isosorbide 5-mononitrate, amyl nitrite and sodium nitroprusside. 
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All these compounds can be viewed as pro-drugs, which, through the release of 
exogenous NO, activate the same metabolic pathway of endogenous NO 
(Torfgard and Ahlner, 1994) and thus can exhibit all its biological properties. 
Nevertheless, their use is substantially confined into the only sphere of 
pathological situations requiring a rapid significant vasorelaxing effect, because of 
their short half-life (i.e. a rapid and massive release of NO).  
In the last two decades, two different biochemical activations for organic nitrates 
were hypothesized and then described: the enzymatic and the non-enzymatic ones. 
The enzymatic pathway, has its primary location on plasma membrane of 
muscular or endothelial cells ( Fung et al., 1992). 
Although the enzymes responsible for the in vivo denitration and reduction of 
organic nitrates have not still identified, different potential enzymes have been 
purposed for this role, such as glutathione-S-transferase (Kurz et al., 1993), 
cytochrome P-450 like enzymes (McGuire et al., 1998), and according to recent 
studies, also mitochondrial aldehyde dehydrogenase (ALDH2) seems able to 
mediate denitration of classical nitrates (Chen et al., 2002). Glutathione-S-
transferase is responsible for the conversion of glyceryl trinitrate (GTN) in its 
metabolites 1,2-GDN and 1,3-GDN (Lau et al., 1990). Such enzyme probably 
uses the reduced thiolic group of glutathione, which is bound to the catalityc 
active site, to release nitroso acid and the glutathione oxidated form. The nitroso 
acid then is reduced to NO, by protonation, or by the formation of of S-
nitrosothiol (Ignarro, 1989). As concerns the non-enzymatic pathway, in the late 
’60, Needleman and coworkers (Needleman and Krantz, 1964; Needleman et al., 
1969) introduced the concept of organic nitrates as “prodrugs” which need 
                                                                                 INTRODUCTION 
 9
intermediates to act their mechanism of action. According to this hypothesis, 
molecules containing SH groups, such as cysteine or glutathione, appeared 
indispensable for the conversion of organic nitrates into NO or S-nitrosothiols 
(Ignarro et al., 1981). Today it is suggested that organic nitrates, interacting with 
sulphydryl groups, produce NO or S-nitrosothiols; these intermediates, activating 
guanylate cyclase, produce cGMP which determines vasodilatation.  
A recent study focuses  the attention on the mechanism of cytochrome P450 
reductase (CYP450R)-mediated nitric oxide and nitrosothiol generation from 
organic nitrates. According to this study the cytochrome P450 reductase catalyzes 
the bioactivation of organic nitrate through reduction to form the intermediate 
organic nitrite, which is converted to NO and nitrosothiols in a thiol-dependent 
reaction. This series of experiments was performed both on rat liver microsomes 
(containing the CYP450R-CYP450 complex) and on purified recombinant 
CYP450R. The presence of NADPH, compared with NADH, results in a much 
more efficient reducing substrate, as electron donor, to support the  CYP450R-
mediated GTN/isosorbide dinitrate (ISDN) reduction to produce nitrite, thanks to 
its better substrate affinity for CYP450R. The CYP450R flavin site inhibitor, 
diphenyleneiodonium, inhibits the NO2 – generation, whereas the CYP450 
inhibitor clotrimazole doesn’t inhibit this first step but gretly inhibits NO2 – -
dependent NO generation. Therefore, CYP450R catalyzes organic nitrate 
reduction, producing nitrite, whereas CYP450 seems to mediate further nitrite 
reduction to NO. However nitrite-dependent NO generation contributed <10% of 
the CYP450R-CYP450 mediated NO generation from organic nitrates suggesting 
that nitrite is not the primary precursor of NO in the process of microsomal 
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CYP450R-CYP450-mediated organic nitrate biotransformation but is the 
precursor of both NO and nitrosothiols. In fact it is well known that sulphydryl 
compounds are needed in GTN activation and that the repeated administration of 
GTN causes sulphydryl depletion and consequent tolerance to further 
vasodilatation. This study shows that the presence of L-cysteine triggered 
significant NO generation from recombinant CYP450R-mediated reduction of 
GTN/ISDN, whereas no detectable NO was generated without the addition of 
thiols. While, with microsomal CYP450R, external thiols were not required for 
NO generation, as the sulphydryl groups in the microsomal proteins may serve to 
reduce organic nitrite to NO. So the proposed mechanism of CYP450R-CYP450-
mediated biotransformationof organic nitrate is the following: 
1° Step 
R-O-NO2 + NADPH + H+  CYP450R     R-O-NO + NADP+ + H2O 
2° Step 
R-O-NO + H2O                  R-O-H + HNO2 
3° Step 
HNO2 + H+    CYP450     NO +H2O 
4° Step 
2R-O-NO + 2R’-SH                    2NO + 2ROH + R’-S-S-R’ 
5° Step 
R-O-NO + R’-SH                  R-OH +R’-S-NO 
According to this mechanism organic nitrite (R-O-NO) is the initial product in the 
process of CYP450R-mediated organic nitrate biotransformation and is the 
precursor of NO and nitrosothiol. In the absence of thiols, organic nitrite 
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undergoes hydrolysis to form nitrite. However in the presence of thiols, either NO 
or nitrosothiols can be formed ( Li et al., 2006). 
Besides the organic nitrates and nitrites, which require a metabolic 
biotransformation for activity (Parrat, 1979), there are direct NO-donors able to 
release NO spontaneously from a nitroso or nitrosyl moiety. 
Although metabolic processes, due to NADPH-generating systems located in the 
cell membrane, seem to be involved in an increased release of NO from sodium 
nitroprusside (SNP), these “facilitating” processes are not required as a necessary 
condition for the NO-release (Kowaluk et al., 1992). Therefore SNP is generally 
classified as an agent belonging to the class of spontaneous NO-donors (Ignarro et 
al., 1999; Ignarro et al., 2002a; Thatcher et al., 2004). In its molecule (Fig. 4), a 
square bipyramidal structure, a nitrosyl group is linked to a ferrous ion connected 
also with five cyanide anions (Ignarro et al. 1999). NO is released from this 
complex at physiological pH. However, the clinical employment of this drug, as a 
vasodilator, is limited by the toxicity due to the formation of thiocyanate and the 
need of parenteral administration (Ignarro et al., 2002). Moreover, SNP exhibits 
the induction of an enhanced hydrogen peroxide-mediated cytotoxicity, probably 
due to the release of cyanide and intracellular residual iron complexes (Wink et 
al., 1996). 
Diazeniumdiolates, also called NONOates (Fig. 3), possess the ability to release 
directly NO as a radical. Their efficacy was demonstrated in reversing cerebral 
vasospasm, reducing pulmonary vascular pressure and their coupling with 
metallic stents is studied in order to reduce the risk of restenosis following 
angioplasty surgical interventions (Keefer, 2003). 
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Figure 5. The two mechanisms accounting for the release of NO from a generic diazeniumdiolate 
(NONOate): if the O-R3 bond is ionic, a H+-catalysed reaction leads to the release of NO (pathway 
A); if the O-R3 bond is covalent, a first biotransformation leads to an intermediate derivative 
(pathway B), which in turn is converted into NO by a H+-catalysed reaction (pathway C). The 
chemical structures of some NONOates, commonly used as NO-donors, are also shown. 
 
Among the direct NO-donors there are two classes of heterocyclic NO-releasing 
drugs, furoxanes and sydnonimines (Fig. 6), which require a facilitator agent to 
release NO. These cofactors are represented by thiol-derivatives for furoxanes and 
by oxidants for sydnonimines. The most known sydnonimine, the 3-
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morpholinosydnonimine (SIN-1), deriving from molsidomine, represents the 
combination of morpholine and a sydnonimine; it has been hypothesised that this 
zwitterionic compound, at physiological pH, decomposes into NO. and superoxide 
anion (Feelisch et al., 1998). Nevertheless, other theories suggest that the 
composition of SIN-1 could lead to nitrogen oxide products, other than NO; these 
products (such as peroxynitrite) could be responsible for toxicity (Wink et al., 
1996).  
N- O CH3
O
N+
N O
N
O
Molsidomine
NH-
N+
N O
N
O
3-Morpholino sydnonimine (SIN-1)
N+N
O
R1
O
R2
O- NN
+
O
R1
O
R2
-O
Furoxan derivatives  
Figure 6. NO-releasing heterocyclic moieties: molsidomine, SIN-1 and generic structures of 
furoxanes. 
 
As concerns furoxanes (1,2,5-oxadiazole 2-oxide derivatives), they are often 
employed as NO-donor moieties linked to “native” drugs in order to add cGMP-
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mediated vasodilating and antiplatelet properties (Ghigo et al., 1992; Feelisch et 
al., 1992). 
Finally, the S-nitrosothiols must be mentioned, a class of NO-donating 
compounds which represent a source of circulating endogenous NO releasing 
spontaneously NO and NO+ (nitrosonium) (Napoli and Ignarro, 2003).  
S-nitrosothiols may also be able to improve transmembrane transfer of NO, 
realised by the cell-surface protein disulfide isomerase (PDI) from a S-nitrosothiol 
source (Zai et al., 1999). Moreover, S-nitrosothiols seem to be involved as 
intermediates, in the organic nitrate mechanism of action. In fact, organic nitrates 
first interact with sulphydryl groups to produce NO (or S-nitrosothiols) which in 
turn activate guanylate cyclase to produce cGMP (which causes vasodilation). 
This biochemical cascade, albeit not indispensable for the mechanism of nitrates, 
seems to be chemically very favourable and rapid (Fung et al., 1992). Besides, 
members of this class, as S-nitroso-N-acetylpenicillamine (SNAP), show some 
advantages with respect to organic nitrates or SNP, in fact they exhibit a lower 
capacity to induce oxidative stress or tolerance in vascular cells (Jaworski et al., 
2001). 
Indeed, the induction of tolerance seems to be one of the most relevant problems, 
related with a long-term administration of many NO-releasing drugs. Although 
the comprehension of the exact mechanisms accounting for the development of 
such a tolerance is still controversial, it is accepted that this represents a 
multifactorial phenomenon involving several (and not completely clarified) 
processes. Besides an early hypo-responsiveness (known as pseudotolerance), 
mainly due to counter-regulatory mechanisms, such as an increased production of 
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endogenous vasoactive compounds, a long-term administration of organic nitrates, 
and in particular glyceryl trinitrate, has been related with many intrinsic 
alterations, leading to a more significant loss of responsiveness (tolerance) (Fung, 
1987; Fung and Bauer, 1994; Munzel et al., 1996; Parker et al., 1991; Abdollah et 
al., 1987; Parker and Parker, 1998; Gori and Parker, 2002a; Gori and Parker, 
2002b; Fung, 2004; Munzel et al., 2005). 
More in general, the tolerance to a NO-releasing agent is a complex phenomenon, 
probably linked to the involvement of several aspects, depending both on the 
chemical nature of the drug and on the triggering of “proximal” and “distal” 
biological mechanisms. The “proximal” events are those related to the alteration 
of one or more steps possibly involved in the bio-transformation of the drug, 
leading to the release of NO, but also those related to the metabolic fate of the 
released NO. Instead, the “distal” mechanisms are those more closely related to 
the possible reduction of the NO-induced rise of cGMP.  
As concerns the “proximal” ones, the induction of tolerance by organic nitrates 
has been studied, taking glyceryl trinitrate as the most commonly used NO-donor 
reference compound. A significant role of a decreased activity of enzymes, such 
as aldehyde deydrogenase 2 (ALDH2) and cytochrome P-450 (both probably 
involved in the bio-activation of glyceryl trinitrate), has been suggested as a cause 
of tolerance. Indeed, ALDH activity was reduced in in vitro models of vascular 
tolerance and ALDH-inhibiting drugs could produce a reduced response to 
glyceryl trinitrate (Chen et al., 2002). However, other in vivo studies led to 
controversial results (Di Fabio et al., 2003), indicating that a decreased enzymatic 
activity of ALDH2 can play a role in the development of tolerance, but this role is 
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not dominant. Instead, an important role played by a decreased activity of 
cytochrome P-450 has been proposed, because the pharmacological induction of 
this enzymatic system could reverse the development of tolerance caused by 
glyceryl trinitrate (Minamiyama et al., 2001), while a vitamin E-deficiency, 
related to a decrease of cytochrome P-450 expression (but also to an increased 
oxidative stress) caused an acceleration in the development of tolerance to 
glyceryl trinitrate ( Minamiyama et al., 2006). Nitrate tolerance seems to derive, at 
least in part, also from an intracellular sulphydryl depletion; this event reduces the 
metabolic conversion of organic nitrates to NO and thereby vasodilation (Fung et 
al., 1992). But some experimental evidences show that non-sulphydryl 
compounds, like enalapril (Katz et al., 1991) and hydralazine (Bauer and Fung, 
1991) can reverse or prevent the occurrence of in vivo nitroglycerine-induced 
tolerance, indicating that the sulphydryl depletion-theory itself is not sufficient to 
explain the mechanisms of nitrate tolerance. Of course, the development of 
tolerance mechanisms, related to a reduced bio-activation of organic nitrates, can 
satisfactorily explain the cross-tolerance between two drugs which share a 
common metabolic activation pathway. On the contrary, this can not account for 
the cross-tolerance observed also between an organic nitrate and a spontaneous 
NO-donor, (or a drug able to release NO through different activation pathway). 
For example, a reduced responsiveness to SIN-1 has been observed in vascular 
preparations obtained from rabbits in which tolerance was induced by glyceryl 
trinitrate (Daiber et al., 2005). Moreover, in the “tolerant” vessels, the authors 
found high levels of superoxide levels and increased amounts of nitrotyrosine, a 
stable metabolite of peroxynitrite. This experimental evidence led to hypothesise a 
                                                                                 INTRODUCTION 
 17
significant role of an accelerated inactivation of NO, as a possible cause of such a 
cross-tolerance (Daiber et al., 2005). Indeed, increased levels of superoxide and of 
peroxynitrite (readly produced by the reaction of surperoxide with NO) have been 
observed in rat vessels made tolerant by glyceryl trinitrate. Consistently, tolerance 
was reduced by pre-treatment with several antioxidant, such as ascorbic acid and 
uric acid (Abou-Mohamed et al., 2004). Finally, also the “distal” mechanisms, 
such as a decreased enzymatic activity of guanylate cyclase (Axelsson and 
Ahlner, 1987) and/or an increased hydrolytic degradation of cGMP (Kim et al., 
2001), can lead to a hypo-responsiveness to NO-donors. Of course, such 
mechanisms can perfectly participate to the multifactorial phenomenon of 
tolerance to organic nitrate and can also explain the tolerance observed for 
spontaneous NO-releasing agents. Indeed, even if the tolerance induced by non-
nitrate NO-donors is generally considered to be of lower magnitude with respect 
to that induced by organic nitrates, relatively high concentrations (0.1-10 μM) of 
SNP determined a significant desensitisation of soluble guanilate cyclase and the 
development of cross-tolerance with authentic NO (Sorajja et al., 2005). However, 
the development of this desensitisation was not observed after treatment with 
lower concentrations (1 nM) of SNP (Sorajja et al., 2005). It is interesting to note 
that some particular effects of NO-donor drugs, such as the anti-platelet one, 
seems to be resistant to the development of tolerance (Holmes et al., 2005). 
The problem of tolerance for NO-donors, whose whole comprehension needs 
further experimental data, has been authoritatively reviewed by some excellent 
papers (Thatcher et al., 2004; Papapetropoulos et al., 1998). 
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NO-donor hybrids 
In the last years, the knowledge of the biochemical and pharmacological 
properties of nitric oxide led to the effort in design of new hybrid molecules, 
which couple a “native” well-known drug with a NO-donor moiety (Fig. 5). This 
innovative approach furnished a variegated sample of new chemical entities which 
conserve the therapeutic efficacy of the “parent” drug, enriched through the nitric 
oxide activity, moreover this “synergism” often resulted in a reverse of their side 
effects.  
Among the NO-donor hybrids an increasing interest was aroused by the NO-
releasing cardiovascular drugs, such as aspirin, statins, α and β-blockers, Ca2+-
antagonists, KATP-openers, ACE-inhibitors and sartans; the goal of these hybrid 
molecules is the improvement of their cardiovascular actions and, sometimes, 
even the elision of their adverse effects thanks to NO properties.  
 
NO-aspirins 
One of the most characterised classes of NO-donors hybrids is represented by 
NO-NSAIDs (NO-donating non steroidal anti-inflammatory drugs) which, 
synthesised by esterifiation of the parent drug (a NSAIDs drug) with a NO-donor 
chain, maintain the original anti-inflammatory properties and show, through the 
nitric oxide action, a marked reduction of gastrolesivity. In fact, NO determines a 
protective effect on gastric mucosa attributable to several pharmacodynamic 
mechanism such as the assurance of mucosal blood flow, the stimulation of the 
mucus production, the inhibition of leukocytary adhesion and of enzymatic 
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caspase (Chiroli et al., 2003; Wallace et al., 1994; Wallace et al., 1995; Moncada 
et al., 1991).  
As concerns the pharmacokinetic, the NO-NSAIDs may be assimilated to organic 
nitrates because they also require metabolic activation before releasing NO. 
Although the enzymes involved are not yet identified, there are a lot of evidences 
about a role of esterases in the cleavage of NO from the parent drug (Burgaud et 
al., 2002; Cirino et al., 1995; Keeble et al., 2001). Nevertheless, even if the 
involvement of esterases is compatible with the chemical structure of NO-
NSAIDs (the NO-releasing moiety is linked to the “native” molecule by an ester 
bond) also cytochrome P450 seems to act in the NO-NSAIDs breakdown (Grosser 
and Schroder, 2000). Moreover, several different experiments on the rate of the 
enzymatic catabolism, both in vitro and in vivo, indicate that NO-NSAIDs have a 
NO-release slower than the “classical” NO-donors, such as SNP or SNAP (Santini 
et al., 1996). This gradual release  may be the key to explain why, in experimental 
animals, NO-NSAIDs do not alter systemic arterial blood pressure even when 
administered intravenously, in large dose, whereas an equimolar dose of the 
“classical” NO-donors causes a deep hypotension (Burgaud et al., 2002). 
A recent study of Knaus’ group shows the development and the biological 
evaluation of a new serie of NO-NSAIDs. Hybrid NO-NSAIDs possessing a 1-
(pyrrolidin-1-yl) diazen-1-ium-1,2-diolate or 1-(N,N-dimethylamino)diazen-1-
ium-1,2-diolate moiety linked by a one-carbon methylene spacer to the carboxylic 
acid group of “native” aspirin (Fig. 6), ibuprofen and indomethacin were 
synthesized and characterised as NSAID and NO-donors. Although these new 
molecules did not show any inhibitory activity against COX1 and COX2, they 
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result in a decreasing of carrageenan-induced rat paw edema similar to that 
exhibited by the “native” drugs and in improving of classical NSAIDs 
ulcerogenity. 
As regards NO-release an increased effect was observed in tests carried out in 
presence of guinea pig serum with respect to those in phosphate buffer solution. 
All these considerations seem to suggest that such compounds are prodrugs which 
require a metabolic activation reaction (esterase-mediated ester cleavage) to be 
active (Velázquez et al., 2005). 
The NO-releasing aspirin derivatives represent a new class of nitric esters in 
which a nitrate group is coupled to the carboxylic moiety of acetylsalicylic acid 
(ASA) through a variety of spacers (aliphatic, aromatic or heterocyclic ones) (Fig. 
7) which result in conferring different pharmacokinetic or pharmacodynamic 
properties to the new hybrid (Chiroli et al., 2003). The nitroaspirin NCX 4016 [3-
(nitrooxymethyl)-phenyl 2-(acetyloxy)-benzoate] is the lead compound of this 
new category of anti-inflammatory and antithrombotic drugs (Del Soldato et al., 
1999) because this chimerical compound is able to maintain the anti-inflammatory 
action without the gastrointestinal toxicity and to show new cardiovascular 
properties due to the NO-donor moiety. 
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Aspirin is the most known NSAID but also its use for the prevention and the 
treatment of such cardiovascular diseases, such as thrombosis, is well established 
(Harter et al., 1979; Hirsh, 1979). The anti-thrombotic effect of aspirin is due to 
the irreversible inhibition of COX-1 which determines a reduction in the 
production of the pro-aggregatory TxA2 by platelets and of the anti-aggregatory 
PGI2 by vascular endothelial cells, but while the endothelial cells are able to 
synthesise new COX-1 enzyme, platelets do not show this possibility, therefore 
the final balance is shifted towards the inhibition of platelet aggregation (Schror, 
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1997). However, aspirin blocks only one pathway of platelet activation thereby 
leaving the others unaffected and this may limit its effectiveness like 
antithrombotic agent (Gresele and Agnelli, 2002; Folts et al., 1999). 
 NO is well known as anti-aggregatory agent, in fact it suppresses platelet 
activation by activating guanylate cyclase (GC), thereby increasing the conversion 
of GTP to cGMP, enhancing calcium ATPase-dependent refilling of intracellular 
calcium stores and inhibiting the activation of phosphoinositide 3-kinase (PI3K). 
As a consequence, intracellular calcium (Ca2+) flux is inhibited, leading to 
suppression of P-selectin expression and of the active conformation of 
glycoprotein IIb/IIIa (GPIIb/IIIa) required for binding fibrinogen (Loscalzo, 
2001). 
Hence, nitroaspirin could represent a good solution for ASA lacks, because its 
mechanism of action results from the sum of COX-mediated effects, such as 
inhibition of biosynthesis of inflammatory prostaglandins and of platelet 
aggregation, and NO-mediated effects (cGMP-dependent and independent) such 
as vasodilation, inhibition of platelet aggregation, leukocyte adherence to the 
vascular endothelium, inflammatory cytokine synthesis (through nitrosylation of 
caspase) and apoptosis (through nitrosylation of caspase and possibly regulation 
of mitochondrial function) (Fiorucci and Del Soldato, 2003). This synergistic 
activity of the two pharmacophoric moieties, aspirin and NO, potentiates the 
pharmacological profile of NCX 4016, in comparison with the “parent” drug, and 
gives to NCX 4016 the status of completely new chemical entity. 
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The effectiveness of NCX 4016 on platelets and on other cellular and metabolic 
functions relevant to thrombosis has been characterized in in vitro studies 
(Gresele et al., 2003a). 
According to these studies, NCX 4016 shows a wider range of action than ASA 
and inhibits platelet aggregation induced by both aspirin-sensitive and aspirin-
insensitive mechanism (Minuz et al., 1995). In fact, NCX 4016 is able to inhibit 
platelet aggregation induced not only by arachidonic acid and collagen, inhibited 
also by aspirin, but also the aggregation induced by U46619, a thromboxane 
analogue, and by thrombin, which are ASA-insensitive (Wallace et al., 1995; 
Minuz et al., 1995; Fiorucci et al., 2001; Mezzasoma et al., 1999; Lechi et al., 
1996; Minuz et al., 2001).  
Since also classic NO donors are able to inhibit the platelet aggregation induced 
by U46619 and thrombin, it seems clear that the NO-moiety of NCX 4016 greatly 
contributes to the antiplatelet property (Wallace et al., 1995; Minuz et al., 1995; 
Mezzasoma et al., 1999; Lechi et al., 1996; Minuz et al., 2001; Wallace et al., 
2002). Moreover NCX 4016 is able, like SNP but differently from aspirin, to 
decrease platelet adhesion to collagen under flow conditions and to prevent shear 
stress-induced platelet activation (Mezzasoma et al., 1999; Negrescu et al., 1995; 
Ruggeri, 1993). These data are interesting, because adhesion is the first step in the 
pathway of platelet activation which leads to thrombus formation and only few of 
the antiplatelet drugs today available are able to prevent it, and a high shear stress 
like that which occurs in stenosed or atheromatous arteries is retained responsible 
for the in vivo platelet activation. 
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Remaining in the vascular district, a possible clinical application of NCX 4016 
seems to be the prevention of restenosis due to neointimal hyperplasia, which 
represent the main long-term complication of  percutaneous transluminal coronary 
angioplasty (PTCA), the most frequent treatment to resolve the coronary 
atherosclerotic stenosis (Cannon et al., 2001). Restenosis is often associated with 
an impairment of NO-dependent pathways: the modulation of the NO-enzymatic 
pathway could influence the development of restenosis, i.e., L-NAME, (L-Nω-
nitroarginine methyl ester, an inhibitor of NO synthase) stimulates neointimal 
hyperplasia. Moreover, NO controls also other pathophysiological responses 
occurring during atherosclerotic restenosis: inflammatory adhesion, vascular 
reactivity, endothelial permeability and regulation of smooth muscle cell 
proliferation linked with the vasculature remodelling. Thereby, as expected, in a 
model of restenosis in hypercholesterolaemic mice, NCX 4016 has been found to 
reduce restenosis more efficiently than aspirin and at lower doses (Ignarro et al., 
2001; Napoli et al., 2001). 
Nitroaspirin could represent also a new approach  for the treatment of saphenous 
vein graft failure which could occur after an autologous saphenous vein coronary 
artery bypass grafting (CABG) and which are represented by thrombosis, 
increasing of media thickening and neointima formation, and proliferation and 
migration of vascular smooth muscle cells (VSMC).  
Aspirin affects thrombosis but not the other responses which are instead inhibited 
by NO, so a NO-releasing aspirin could be a strategy to contrast all these aspects 
(Shukla et al., 2003). 
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Finally, an intriguing application for NCX 4016 seems to be represented by a 
cardioprotective role in myocardial ischemia-reperfusion process. Aspirin is 
presently used for reducing mortality from acute myocardial infarct but its effects 
are most likely due to prevention of re-infarction rather than a direct 
cardioprotective effect, i.e. on arrhythmias (Verheugt et al., 1990). 
NCX 4016 reduces infarct size in several animal models but recently its activity 
has been well characterized in rats. NCX 4016 showed remarkable 
cardioprotection in rats submitted to myocardial ischemia/reperfusion, as was 
evident in the reduction of ventricular premature beats and in the incidence of 
ventricular tachycardia and fibrillation; these arrhythmias were reduced dose-
dependently, resulting in survival of all rats treated with higher dose of NCX 
4016. Also the infarct size was restricted proportionally to the dose of NCX 4016 
and this action was associated with biochemical data such as diminution of both 
plasma creatine phosphokinase and cardiac myeloperoxidase activities (Rossoni et 
al., 2001). 
An exhaustive overview on the interesting pharmacological properties and on the 
relatively safe toxicological profile of NCX 4016, emerging from both pre-clinical 
and the first clinical studies has been recently published (Di Napoli and Papa, 
2003). In this article no mention is done about the possible induction of tolerance. 
However, a bidirectional cross-tolerance between NCX 4016 and glyceryl 
trinitrate has been described in an in vitro study (Grosser et al., 2000). 
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NO-statins 
Inhibitors of 3-hydroxy-3methylglutaryl CoA reductase, also called statins, are the 
most employed drugs in the treatment of hypercholesterolemia. The efficacy of 
statins in reducing low-density lipoprotein-cholesterol levels has been confirmed 
by several clinical trials (Heart Protection Study Collaborative Group, 2002). 
However, in the last years, the theory of the “pleiotropic effects” of statins is 
raising. According to this hypothesis, there are other mechanisms of action, 
beyond lipid-lowering activity, which participate to the beneficial effects of 
statins in atherosclerotic disease (Bonetti et al., 2003; Marz and Koening, 2003). 
In fact, statins are able to elicit an increase in endothelial NO production which 
leads to an anti-inflammatory action at the endothelium level and to an inhibition 
of VSMC proliferation (Weutz-Schmidt, 2002); but often, especially in those 
diseases like atherosclerosis and diabetes, there is an impairment of endothelium 
function which reduces the production of endogenous NO, so NO-releasing statins 
could offer an alternative source of NO for the therapies of these pathologies. 
A recent study on the NO derivatives of pravastatin (NCX 6550) and fluvastatin 
(NCX 6553) (Fig. 8) shows that the NO-donor moiety significantly potentiates the 
nonlipid-lowering mechanism of action of native statins. 
For example, as concerns the restoration of endothelial function, NO-releasing 
statins determine a reduction in both smooth muscle cells proliferation and 
inflammatory events, beyond those induced by statins alone in atherosclerosis 
(Ongini et al., 2004). 
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Figure 8. Chemical structures of pravastatin, fluvastatin and atorvastatin, with their 
corresponding NO-releasing hybrid derivatives. 
 
 
 A chronic treatment with the nitropravastatin derivative, NCX 6550, is able to 
improve the endothelial dysfunction also in spontaneously hypertensive rats 
(SHR), a model with marked vascular dysfunction and normal levels of 
cholesterol (Presotto et al., 2005). Moreover the NO moiety brings additional 
properties to the native statins, as demonstrated by NCX 6550 which showed the 
capacity to inhibit platelet aggregation in vitro, and to reduce mortality in the 
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thromboembolism mouse model (Gresele et al., 2003b). More recently the 
nitropravastatin ability of improve neovascularisation and recovery from limb 
ischaemia in type-1diabetic mice was also demonstrated; not only but in the same 
study it was also showed that the in vitro pre-incubation with NCX 6550 
completely reversed the reduced migratory capacity of endothelial progenitor cells 
due to high glucose concentration only partially reversed by pravastatin (Emanueli 
et al., 2007). Finally, the last derivative, the NO-releasing atorvastatin (NCX 
6560) (Fig. 7), has been recently compared with atorvastatin in cell-based assays 
as well as in normal and hypercholesterolaemic mice. These studies show a 
retained HMG-CoA reductase inhibitory activity but, at the same time, in a model 
of platelet pulmonary thromboembolism in mice, NCX 6560, significantly 
reduced mortality, while an equimolar dose of atorvastatin was ineffective. 
Moreover in LDLR (Low Density Lipoprotein Receptor) knock-out mice fed with 
hyperlipidemic diet, NCX 6560, but not atorvastatin, significantly reduced ex vivo 
platelet adhesion to collagen under high shear rate (Monopoli et al., 2005). More 
in particular, recently, it has been observed that, in hyperlipidemic mice, NCX 
6560 was more effective than atorvastatin at lowering serum cholesterol; not only 
but its ability to induce vasodilation, cGMP formation and to reduce epinephrine-
induced platelet pulmonary thromboembolism in mice was confirmed. Finally this 
new molecule seems to exert also an anti-inflammatory activity reducing iNOS 
expression and TNFα release in LPS (lipopolysaccharide)-trated macrophages 
(Momi et al., 2007). 
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NO-Sildenafil 
Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5) and it is the 
pioneer drug in the oral therapy of erectile dysfunction. Its mechanism of action 
consists in the inhibition of a cGMP phosphodiesterase V subtype, particularly 
present in penile smooth muscle; in this way, it prevents cGMP hydrolysis, thus 
allowing a prolonged signalling actions of NO (Corbin and Francio, 1999). 
In patients with stable angina, co-administration of sildenafil with organic nitrates 
produces significant reductions in blood pressure, greater than those induced by 
nitrates alone. On the basis of these findings, sildenafil should not be associated to 
a therapy with nitrates because it could lead to an exacerbation of negative and 
potentially life-threatening cardiovascular consequences (Kloner, 2000). 
Although the association of sildenafil with NO-donors seems to be deleterious, in 
last years a nitroderivative of sildenafil, NCX-911 (Fig. 9), has been synthesised. 
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Figure 9. Structures of sildenafil and its nitrate salt derivative, a well-representative example of 
effective NO-releasing hybrid, based on a simple chemical manipulation. 
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 By a chemical point of view, it could be probably considered as a simplest and 
effective example of pharmacodynamic hybrid: the NO-donor property has been 
conferred to the “native” sildenafil through the conversion in its corresponding 
nitrate salt. A lot of studies were carried out on this new molecule: thus, NCX-911 
was found to be as potent as sildenafil in inducing relaxation of rabbit corpus 
cavernosum, but in the presence of L-NAME (a NO synthase inhibitor) the 
potency of NCX-911 was not altered, while sildenafil potency decreased five-fold. 
This result suggests that NO-releasing PDE5 inhibitors could potentially be more 
useful than PDE5 inhibitors in the treatment of erectile dysfunction, in conditions 
of reduced availability of endogenous NO (Kalsi et al., 2004a). For example, in 
diabetes the endogenous NO is significantly decreased and a comparative study 
between NCX-911 and sildenafil on the anococcygeus muscle of diabetic rats 
showed that the potency of NCX-911 in reducing the phenylephrine-induced tone 
was not altered, while that of sildenafil was significantly reduced (Kalsi et al., 
2004b). Another cardiovascular disease, hypercholesterolaemia, promotes erectile 
dysfunction through increased superoxide formation and negation of NO 
bioactivity in cavernosal tissue. Although the origin of this mechanism was still 
not explained, the effect of sildenafil citrate and NCX-911 was studied on 
cavernosal tissue of hypercholesterolaemic rabbits. The results of this study seem 
to suggest that NO donating sildenafil may be therapeutically more beneficial than 
conventional sildenafil in treating erectile dysfunction with an oxidative stress-
related aetiology (Shukla et al., 2005). 
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NO-releasing anti-adrenergic drugs 
In the cardiovascular district, the effects of the adrenergic system are mainly 
mediated by the subtypes 1 and 2 of its α and β receptors. In particular α1 
receptors, when activated, are able to exert vasoconstriction at peripheral level 
through the transductional system in which IP3 and DAG are involved as second 
messengers. The use of α1-antagonist as vasodilators is exercised since several 
years but, in the last decade, new NO-donor α1-antagonists were synthesised by 
replacing the furan ring of prazosin (a well known α1-blocker) with a furoxan 
derivative (Fig. 10), to obtain a series of well balanced hybrids in which the 
vasodilation mediated by α1-antagonism was integrated with the NO-mediated one 
(Fruttero et al., 1995). Of course, this strategy led to a structural change of the 
“native” drug, rather than to a cleavage of the “native” prazosin, following the 
release of NO. 
Nevertheless, among the adrenergic receptors, the principal target for 
antihypertensive therapy is undoubtedly represented by the β ones. As concerns 
the cardiovascular system, the β1 receptors are principally distributed at cardiac 
level and their activation determine a positive inotropic, chronotropic, 
batmotropic and dromotropic effect; the β2 receptors, instead, are responsible of 
the vasodilation in the skeletal muscle district but their involvement as 
antihypertensive target is limited. Besides, the β1 receptors are widely expressed 
also at the level of renal macula densa, where their block prevents the release of 
renin and as a consequence, contrasts the formation of angiotensin II through the 
renin-angiotensin system (RAS). Thereby, selective β1-blockers exert their 
antihypertensive effects through several pharmacodynamic patterns, and today 
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they are commonly used not only to counteract hypertension, thanks to the 
reduction of cardiac activity and the block in renin release, but also in angina 
pectoris, thanks to the reduction of cardiac consumption of O2, and in cardiac 
arrhythmias. 
Recently, in order to potentiate some β1-blockers activities, such as the lowering 
effects on the blood pressure and the decreasing in oxygen consumption, several 
hybrid molecules were synthesised, in which different NO-moieties (furoxanes, 3-
nitrooxypivaloyl acid, N-acetyl-D-penicillamine) were linked to chemical 
structures, closely related with propranolol (Fig. 10) (Boschi et al., 1997; Decker 
et al., 2004). 
Some of these new hybrid molecules were well-balanced and exert both the β-
blocking and the NO-releasing actions in the same range of concentration, but in 
general, compared with propranolol, the hybrid formation lowers the affinity for 
β-receptors, in particular for the β2-type, to give an increase in β1/ β2 selectivity 
(Boschi et al., 1997). 
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Figure 10. Chemical structures of prazosin (α1-blocker) propranolol and metoprolol (β-blockers) 
and their NO-releasing analogues. When the NO molecules are metabolised, lead to new 
compounds. Nipradilol possesses a nitrooxy group, conferring NO-releasing properties. Nebivolol 
does not possess any NO-releasing moiety, nevertheless it is able to induce an increased release of 
endothelial NO and thus, nebivolol shows pharmacological effects which can be assimilated to 
those produced by a hybrid NO-β-blocker. 
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An interesting new hybrid β-blocker is represented by a S-S enantiomer of a 
metoprolol-related derivative, PF9404C, studied and developed in order to correct 
the initial high peripheral resistance occourring in hypertensive patients treated 
with β-blockers. On the other hand, due the β-blocker activity, it could prevent the 
increase of heart rate and catecholamine levels which represent the reaction to a 
fall of peripheral resistance and blood pressure. 
In a previous study PF9404C was compared with rapid NO-donors producing an 
immediate but transient vasorelaxation and what was new is that, on the contrary, 
it seems able to evoke a slowly developed but sustained relaxation (Villaroya et 
al., 1999). 
Moreover, although classic nitrovasodilators were often associated with β-
blockers as an efficient therapeutic approach in coronary heart disease, the 
phenomenon of tolerance, rising in chronic treatment, could not be ignored. A 
recent study demonstrates that if compared with nitroglycerin, PF9404C shows 
much lesser tolerance. This lower induction of tolerance by PF9404C could be 
explained through its slower release of NO (Ruíz-Nuño et al., 2004). 
 
 
Nipradilol (3,4-dihydro-8-(2-hydroxy-3-isopropyl-amino)-propoxy-3-nitroxy-2H-
1-benzopyran) (Fig. 9) is a nonselective adrenoceptor blocking agent with a weak 
β-adrenoreceptor blocking activity and direct vasodilating property due to a nitro 
group contained within its molecular structure (Uchida et al., 1983). Nipradilol 
showed beneficial effects on cardiac remodelling, ischemic heart diseases and 
blood pressure control (Kosegawa et al., 1998; Sonoki et al., 1997), and its 
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involvement on both intracellular calcium mobilization and the content of cGMP 
was proposed to partially explain its pharmacological action (Nitta et al., 1998). In 
a recent study it was hypothesised that mechanical stress-induced activation of 
intracellular signal transduction cascades is controlled by nipradilol in human 
aortic smooth muscle cells (HASMC) (Iizuka et al., 2004). In fact, in endothelial 
cells, mechanical stresses are able to stimulate one or more phosphorylation 
cascades leading to an activation of mitogen-activated protein kinases (MAPKs) 
(Tseng et al., 1995). Also hypertension and angioplasty are rapid inducers of 
MAPKs activation in vivo (Pyles et al., 1997). These findings confirm that 
nipradilol has an action in modulating intracellular signal transduction pathway, 
i.e. extracellular signal-regulated kinase (ERK) cascade under high atmospheric 
pressure on HASMC (Iizuka et al., 2004), but classical β-blockers are reported to 
lack an inhibitory effect on SMC proliferation (Brehm et al., 2001). Therefore, the 
anti-proliferative effect of nipradilol on HASMC was thought to be caused by the 
release of NO itself (Iizuka et al., 2004). Different studies suggest that nipradilol 
is a potent NOS stimulator in endothelial cells with NO releasing action, so this 
drug could represent a substitute for injured endothelial cells with a possible role 
in the treatment of endothelial dysfunctions occurring in atherosclerosis, 
hyperlipidemia and hypertension (Zeiher et al., 1993; Jaychandran et al., 2001). 
Finally, nipradilol mimics a cardioprotective mechanism called  preconditioning. 
Preconditioning represents a protective system in which a brief period of 
ischemia, preceding a most important ischemia, determines a markedly reduced 
infarct size. This physiological endogenous mechanism can be mimicked through 
the administration of some exogenous drugs, such as ATP-sensitive potassium-
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channel openers, adenosine, etc. (Parrat and Kane, 1994; Yao and Gross, 1993; 
Yokota et al., 1995). Nitric oxide is retained to be involved in the mechanism of 
preconditioning (Vegh et al., 1992), and recent studies have shown that NO is a 
requisite for cofactor in the preconditioning response generated by the 
administration of ATP-sensitive potassium-channel openers (Horimoto et al., 
1998). After a coronary surgical intervention a lot of patients receive β-blockers, 
but β-adrenoceptors blockade alone prevents preconditioning, so the proposal to 
administer nipradilol may simultaneously offer a β-blocking action and a NO-
mediated preconditioning. As concerns mechanical function, nipradilol may exert 
its effect by increasing coronary flow after the reperfusion (Horimoto et al., 
1999). 
Although nebivolol is not a molecule able to release exogeous NO (Fig. 9), it is 
able to induce an increased release of endothelial NO (as better explained below). 
Even if it can not be considered as a true “bifunctional” drug, nevertheless it 
shows pharmacological effects which can be assimilated to those produced by a 
hybrid NO-β-blocker. Nebivolol is a racemic mixture of equal amounts of the two 
enantiomers D an L, which belongs to the class of the high cardioselective, non-
hybrid, β-adrenergic receptor antagonists. Its peculiarity is that nebivolol 
possesses vasodilator properties, which are not due to the block of adrenergic 
receptors on smooth muscle cells. This vasodilator response is attributed to L-
nebivolol and experimental evidence indicates that it is due to endothelium-
dependent mechanism involving NO and the L-arginine/NO pathway (Van de 
Water et al., 1988; Gao et al., 1991; Cockroft et al., 1995). Recent in vitro 
findings show that nebivolol relaxes vascular smooth muscle by mechanism 
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involving the NO-cyclic GMP system (Ignarro et al., 2002b); these observations 
are predictive of in vivo effects in patients and support the findings that nebivolol 
reverses endothelial dysfunction in patients with essential hypertension (Tzemos 
et al., 2001). Finally, nebivolol is also able to inhibit vascular smooth muscle cell 
proliferation by mechanisms involving NO but not cyclic GMP (Ignarro et al., 
2002c). 
 
NO-releasing dihydropyridines 
The 1,4-dihydropyridine (DHP) Ca2+-antagonists, such as nifedipine, nitrendipine, 
amlodipine, are widely used in the treatment of hypertension and ischemic heart 
diseases. Their principal mechanism of action consists in the inhibition of Ca2+-
influx through voltage-dependent L-type calcium channels (VDCCs) in vascular 
smooth muscle (Godfraind, 1994; Kuriyama et al., 1995). Besides the effects on 
the vascular smooth muscle, there are studies which reported that amlodipine may 
release nitric oxide from canine coronary microvessels through modulating the 
actions or formation of kinins; however, the mechanism by which calcium 
antagonists release NO is still unclear because there is no known receptor for 
Ca2+-antagonists in endothelial cell (ECs) (Zhang and Hintze, 1998) and most ECs 
lack VDCCs, so endothelial depolarization fails to increase the intracellular Ca2+ 
concentration through VDCCs (Nilius et al., 1997). Recently, it has been found 
that vascular smooth muscle and endothelial cells are tightly coupled via myo-
endothelial communication and that electrical signals can be conducted each other 
(Yamamoto et al., 1999; Murai et al., 1999). This finding suggests that the 
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modulation of electrical signals in smooth muscle by DHPs could affects 
membrane potential in ECs (Muraki et al., 2000). 
In order to potentiate their vasorelaxing properties, DHP Ca2+-antagonists were 
structurally modified by the addition of furoxan moieties which act as NO-donors. 
So a new series of 4-phenyl-1,4-dihydropyridines, bearing furoxan moieties at the 
ortho or meta position of the phenyl ring was synthesized (Fig. 11) and 
pharmacologically characterised, allowing to distinguish the well balanced hybrid 
molecules from that having a Ca2+-antagonist  or NO-donor dominant profile (Di 
Stilo et al., 1998).  
Finally, in the last years, also the properties of NO-donor Ca2+-agonists were 
investigated: in fact, when an appropriate group, such as the nitro group, is 
inserted in one of the two ester functions of the 1,4-dihydropyridine structure, the 
resulting two enantiomers display opposite pharmacological profile as in Bay K 
8644, in which the (-)-S-antipode is a potent agonist at L-type Ca2+-channels while  
the (+)-R-antipode is a weak antagonist (Goldmann and Stoltefuss, 1991). Ca2+-
agonists are positive inotropic agents so they are potentially useful for the 
treatment of the congestive heart failure (CHF), but their capacity to increase Ca2+ 
levels in vascular smooth muscle represent a limit because it leads to 
vasoconstriction. The combination of these 1,4-DHPs able to activate L-type 
Ca2+channels with a NO-donor moiety (2-nitrooxyethyl esters, furoxanes or 
diazeniumdiolates) (Fig. 9) could represent a strategy to overcome this adverse 
effect and therefore to realize a new class of hybrid compounds which show a 
positive inotropism devoid of vasoconstriction (Visentin et al., 2004; Velázquez 
and Knaus, 2004); Shan and Knaus, 1999; Shan et al., 2002). 
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Figure 11. Chemical structures of the dihydropyridines nifedipine and Bay K8644 (respectively, 
calcium antagonist and calcium-agonist), and of their NO-releasing analogues. When the NO-
dihydropyridines are metabolised, lead to new compounds. 
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Nicorandil 
Nicorandil, N-(2-hydroxyethyl)-nicotinamide nitrate ester (Fig. 12), is an hybrid 
anti-anginal drug that possesses the characteristics of both an ATP-sensitive 
potassium channel (KATP) opener and a NO-donor.  
N
H
N
O
ONO2
Nicorandil  
Figure 12. Chemical structure of nicorandil. This KATP –activator shows a nitrooxy group, 
conferring the NO-donor property, as an additive pharmacodynamic feature. 
 
Nicorandil exerts its vasodilating effect through a dual mechanism of action: as a 
nitrovasodilator it activates the guanylate cyclase increasing the cGMP formation 
and these events lead to a relaxation of vascular smooth muscle. As a KATP opener 
nicorandil determines the hyperpolarization of the surface membrane which 
causes the closure of voltage-dependent ion channels and the reduction of free 
intracellular calcium ions and even this pathway leads to a vasodilatory effect. 
Due to its KATP opener profile, nicorandil dilates peripheral and coronary 
resistence arterioles while the nitrate moiety allows it to dilate systemic veins and 
epicardial coronary arteries. So nicorandil increases coronary blood flow, reduces 
preload and afterload (Taira, 1987; Yokota et al., 1987) and exerts an anti-anginal 
effect comparable with the nitroglycerin one (O’Rourke, 1996; Satoh et al., 1993). 
However nitrate therapy might induce the development of tolerance, increase 
vascular sensitivity to vasoconstrictors (Elkyan, 1991) and deteriorate endothelial 
function (Caramori et al., 1998). Indeed nicorandil, due to its dual mechanism of 
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action, is able to determine vasorelaxation even in nitrate-tolerant blood vessel 
through the opening of KATP channel ( IONA, 2002). 
Moreover the clinical trial “Impact of Nicorandil in Angina” (IONA study) 
showed that nicorandil improves the prognosis of patients with stable angina 
pectoris by reducing the frequency of acute coronary syndrome (ACS) (IONA, 
2002). Recent studies seem to suggest that this reduction is possible because 
nicorandil may be able to inhibit intracoronary thrombus formation through 
modification of the type-1 plasminogen activator inhibitor (PAI-1) (Sakamoto et 
al., 2004). In last years, several studies demonstrated that the activation of 
mitochondrial KATP (mito KATP) channel by diazoxide is able to inhibit apoptosis 
induced by oxidative stress in cardiac myocytes; the same studies found that also 
nicorandil exerts an anti-apoptotic action through the activation of mitoKATP 
(Akao et al., 2001; Akao et al., 2002). More recent experimental findings, 
obtained through the coapplication of the mitoKATP channel antagonist 5-
hydroxydecanoate (5-HD) and of the inhibitor of soluble guanylate cyclase ODQ 
(1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), on cultured myocytes treated with 
hydrogen peroxide and nicorandil, seems to indicate that also the nitrate-like 
effect contributes to the inhibition by nicorandil of apoptosis induced by oxidative 
stress in cardiac myocytes (Nagata et al., 2003). 
Finally, nicorandil is known as a cardioprotective agent acting in the ischemic 
preconditioning through the opening of mitoKATP channels, however the exact 
mechanism of action is still unclear, probably involving several components (Sato 
et al., 2000; Iwai et al., 2002). For example, a key role seems to emerge for NO 
which, according to recent data, selectively activates mitoKATP channels through 
                                                                                 INTRODUCTION 
 42
the protein kinase C (PKC) translocation from the cytosolic to the mitochondrial 
fraction (Harada et al., 2004). The pivotal role of  PKC, in cardioprotection upon 
ischemia-reperfusion has been reported (Kawamura et al., 1998; Liu et al., 1994; 
Mitchell et al., 1995). Therefore, probably nicorandil exerts its anti-ischemic 
effect through synergistic mitoKATP channel opening generated by a direct effect, 
together with NO-donor activation of PKC; this dual mechanism of action could 
explain the greater effectiveness of nicorandil in comparison with  other pure 
KATP channel openers (Harada et al., 2004). 
 
NO-ACE inhibitors 
ACE inhibitors, such as captopril, enalapril etc. represent a first-choice class of 
drugs in the pharmacotherapy of hypertension and congestive heart failure: they 
act on renin angiotensin system (RAS) preventing the conversion of angiotensin I 
to angiotensin II (AII) by the Angiotensin Converting Enzyme (ACE). In last 
years, in order to potentiate the ACE inhibitors properties, a S-nitrosylated 
derivative of captopril, S-nitrosocaptopril (SNOcap) (Fig. 13), was synthetized 
and characterized (Jia and Blantz, 1998). Its NO-donor and ACE inhibiting 
actions emerge after the homolytic cleavage of the S-NO bond, under 
physiological conditions (Jia et al., 1999). The pharmacological properties of 
SNOcap have been described in systemic vessels, in vitro (Loscalzo et al., 1989; 
Cooke et al., 1989) and in vivo (Shaffer et al., 1991; Nakae et al., 1995). Due to 
the dual mechanism of action, S-nitrosocaptopril is effective in hypertension, 
platelet aggregation, congestive heart failure and pulmonary hypertension, 
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potentiating the effect of the native captopril (Tsui et al., 2003). This improved 
mechanism of action is due not only to the sum of the two components.  
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Enalapril NO-Enalapril (NCX-899)  
Figure 13. Chemical structures of the ACE-inhibitor drugs captopril and enalapril and of their 
NO-releasing hybrids. In such hybrids, the removal of the NO-donor moieties leads to the original 
“native drugs, without any structural alteration. 
 
Recently, Ackermann et al. showed that NO and NO-releasing substances can 
competitively inhibit ACE (Ackermann et al., 1998) and this finding was 
confirmed by other studies on porcine iliac arteries (Persson and Andersson, 
1999) and on rats pulmonary artery (Tsui et al., 2003), comparing SNOcap with 
the parent drug, captopril. Finally, the toxicity of SNOcap was examined in 
rodents: the absence of adverse effects in subchronic toxicity studies makes 
SNOcap a good candidate for further clinical trials, but it could cause a severe 
hypotension when overdosed (Jia et al., 2001). 
More recently, a new compound, NCX 899, a NO-releasing derivative of enalapril 
(Fig. 13) was synthetized and characterized, evaluating its action on 
cardiomyopathic hamsters with heart failure. NCX 899 is a slow NO-donor and 
the cleavage of the native molecule from the NO-moiety is due to the action of 
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esterases. If compared with enalapril alone, NCX 899, appears more effective in 
enhancing vascular effects, increasing left ventricular contractility and preventing 
unfavourable remodeling, consistently with a vascular delivery of exogenous NO 
which determines an improvement in endothelial function and a reduction of 
vascular resistence (Iwanaga et al., 2004). Moreover, in a recent study, the 
pharmacokinetics and pharmacodynamics of NCX899 was evaluated in male 
beagles: the results showed that NCX899 presented pharmacokinetic 
characteristics similar to the native drug enalapril and it maintained the ACE-
inhibiting profile but it was also effective in protecting against the raise of arterial 
blood pressure and the concomitant bradycardia induced by an i.v. administration 
of the NO-synthase inhibitor, L-NAME (Okuyama et al., 2007). 
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CHAPTER 2 
 
 
 
NO-DONOR LINKERS: EVALUATION OF THEIR 
DIFFERENT NO-RELEASING PROPERTIES* 
 
*The contents of chapter 2 have been already published: 
 
Calderone V., Digiacomo M., Martelli A., Minutolo F., Rapposelli S., Testai 
L., Balsamo A.  
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Introduction 
 
In order to obtain a multi-target drug possessing NO-donor properties, it was 
important to conjugate the NO function to another drug with an easily cleavable 
group. The ester-based linker is a cleavable group which, as a result of the action 
of plasma esterases, is capable of releasing two individual drugs (nitric oxide and 
the “native drug” ), which act independently. 
In the last few years, many cleavable conjugates have been described (see 
Introduction) containing an NO-releasing functionality linked via an ester group 
to a known “native” drug.  
The chemical strategies usually employed to add NO-donor properties to a 
“native” drug involved its conjugation with different nitrogen-containing 
molecular portions. Among them, the nitrooxy moiety, conjugated to a “native” 
drug often through a molecular linker, probably represented the most convenient 
approach.In order to ensure an appropriate conjugation between the NO-donor 
linker and a potential native drug, the nitrooxy group was inserted into different 
structures possessing  carboxylic, phenolic  or alcoholic functions suitable to form  
a vulnerable bond such as the ester one. On this basis, with the aim of study the 
pharmacologic properties of these NO-donor structures potentially useful to build 
up new pharmacodynamic hybrids, the nitrooxymethyl-benzoic acids (Ar-NO 
[1a]; p-Ar-NO [1b]; Ar-NO-α-Me [2a]; p-Ar-NO-α-Me [2b]; Ar-NO-2,6-Me2 
[3]) and the 2-nitrooxymethyl-pyridinecarboxylic acid (Pyr-NO [4]) have been 
synthesised; furthermore, as hydroxy-functionalised linkers the phenol derivative 
(Phen-NO [5]) and four nitrooxymethyl-benzylic alcohols (Benz-NO [6a]; p-
Benz-NO [6b]; Benz-NO-α-Me [7a]; p-Benz-NO-α-Me [7b]) were also 
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synthesised (Scheme 1,2). In Scheme 1 is represented the general procedures 
following to obtain nitrooxy derivatives. As concern compounds Ar-NO, p-Ar-
NO, Ar-NO-2,6-Me2, Phen-NO, Benz-NO and p-Benz-NO  they were obtained 
by reaction of the corresponding chloro-derivatives with silver nitrate in 
acetonitrile (method A, sch. 1), while compounds Ar-NO-α-Me, p-Ar-NO-α-Me 
and Pyr-NO were obtained by reaction with nitric acid and acetic anidride at –10 
°C (method B, sch. 1). As concern compounds Benz-NO-α-Me, p-Benz-NO-α-
Me, these were synthesised starting from the appropriate acetylbenzoic acids 
(8a,b), which were reduced to the corresponding benzyl-alcohols 9a,b with 
LiAlH4 in THF (Scheme 2). The treatment of a solution of  9a,b in toluene with 
concentrated HCl afforded the monochloro derivatives 10a,b which were 
submitted to reaction with AgNO3  in CH3CN to yield the corresponding nitro 
esters 7a,b (Scheme 2).   
Scheme 1. 
 
Method A 
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                                                                                               1, 3, 5, 6 
I: AgNO3, CH3CN, r.t. 
 
 
Method B 
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                                                                                                            2, 4 
I: HNO3 conc., Ac2O,  r.t.. 
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Scheme 2. 
 
 
i: LiAlH4, THF, r.t.; ii: HClconc., toluene, r.t., iii: AgNO3, CH3CN, r.t. 
 
Table 1. NO-donor linkers with a carboxy (1a,b-4), phenolic (5) or hydroxymethyl function 
(6a,b-7a,b). 
 
     Compound X R R1 R2 R3 
Ar-NO             
(1a) C H H H COOH 
Ar-NO-α-Me        
(2a) C Me H H COOH 
Ar-NO-2,6-Me2          
(3) C H Me Me COOH 
Pyr-NO             
(4) N H - H COOH 
Phen-NO           
(5) C H H H OH 
Benz-NO           
(6a) C H H H CH2OH 
 
Benz-NO-α-Me     
(7a) C Me H H CH2OH 
p-Ar-NO             
(1b) C H H H COOH 
p-Ar-NO-α-Me     
(2b) C Me H H COOH 
p-Benz-NO           
(6b) C H H H CH2OH 
 
p-Benz-NO-α-Me 
(7b) C Me H H CH2OH 
COOH
O
OH
OH
OH
Cl
OH
O2NO
i ii
iii
8a,b 9a,b 10a,b
7a,b
a: meta 
b: para
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Pharmacological procedures 
 
All the experimental procedures were carried out following the guidelines of the 
European Community Council Directive 86-609. The experimental protocol was 
approved by the Animal Care Committee of the University of Pisa. 
The compounds were tested on isolated thoracic aortic rings of male normotensive 
Wistar rats (250-350 g). 
After a light ether anaesthesia, the rats were sacrificed by cervical dislocation and 
bleeding. 
The aortas were immediately excised and freed from extraneous tissues, and the 
endothelial layer was removed by gently rubbing the intimal surface of the vessels 
with a hypodermic needle. Five millimeter wide aortic rings were suspended, 
under a preload of 2g, in 20mL organ baths, containing Tyrode solution 
(composition in mM: NaCl 136.8; KCl 2.95; CaCl2 1.80; MgSO4 7H2O 1.05; 
NaH2PO4 0.41; NaHCO3 11.9; Glucose 5.5), thermostated at 37°C and 
continuously gassed with a mixture of O2 (95%) and CO2 (5%). Changes in 
tension were recorded by means of an isometric transducer (Grass FTO3), 
connected to a preamplifier (Buxco Electronics) and to data acquisition software 
(BIOPAC Systems Inc., MP 100). 
After an equilibration period of 60 minutes, endothelium removal was confirmed 
by the administration of acetylcholine (ACh) (10 μM) to  KCl (30 mM)-
precontracted rings. A relaxation < 10% of the KCl-induced contraction was 
considered to be indicative of an acceptable lack of the endothelial layer, while 
organs showing a relaxation ≥ 10% (i.e., a significant presence of the 
endothelium) were discarded. 
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NO-mediated vasorelaxing effect: concentration-response curves 
 
From 30 to 40 minutes after the confirmation of endothelium removal, aortic 
preparations were contracted by a single concentration of KCl (30mM), and when 
the contraction reached a stable plateau, 3-fold increasing concentrations of the 
test substances (from 1 nM to 100 μM) were added. 
Preliminary experiments showed that the KCl (30 mM)-induced contractions 
remained in a stable tonic state for at least 40 minutes. 
The same experiments were carried out in the presence of a well-known guanylate 
cyclase inhibitor, ODQ (1 μM), which was incubated in aortic preparations after 
confirmation of endothelium removal. 
Time-course of  vasorelaxing effect 
From 30 to 40 minutes after confirmation of endothelium removal, aortic 
preparations were contracted with a single concentration of 30mM KCl,  and after 
the reaching of a stable plateau a single concentration (1 μM) of the compounds 
was added. The vasorelaxing effects of the added compounds was monitored for 
50 minutes. 
Data analysis 
The vasorelaxing efficacy was evaluated as the maximal vasorelaxing response, 
expressed as a percentage (%) of the contractile tone induced by 30mM KCl. 
When the limit concentration of 100 μM (the highest concentration that could be 
administered) of the test compounds did not reach the maximal effect, the 
parameter of efficacy represented the vasorelaxing response, expressed as a 
percentage (%) of the contractile tone induced by 30mM KCl, evoked by this limit 
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concentration. The parameter of potency was expressed as pIC50, calculated as the 
negative logarithm of the molar concentration of the test compounds evoking a 
50% reduction of the contractile tone induced by 30mM KCl. The pIC50 could not 
be calculated for those compounds showing an efficacy parameter lower than 50 
%. The above experimental data were obtained by a computer fitting procedure 
from the concentration-response curves (software: GraphPad Prism 4.0). 
In order to describe the time-course profiles of the effects, the “effect vs time” 
curves were analysed by a computer fitting procedure (software: GraphPad Prism 
4.0), using the following equation: 
Eff = (EM x T) / (Kt + T) 
where : 
Eff is the vasorelaxing effect (expressed as a percentage of the contractile tone 
induced by KCl 30 mM) recorded at each min, after the administration of the test 
compounds (1 μM). 
EM is the highest vasorelaxing effect (expressed as a percentage of the contractile 
tone induced by KCl 30 mM) induced by the test compounds (1 μM). 
T is the time, expressed in min, correlated to a given Eff. 
Kt is the time (in min) required to reach an Eff = ½ EM 
This analysis allowed us to calculate the parameter of T25 (time, in min, required 
to reach an equi-effective level of vasorelaxing effect = 25% of the contractile 
tone induced by KCl 30 mM).  
The parameter of T25 could not be calculated for those compounds exhibiting an 
EM lower than or close to 25. 
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The parameters of pIC50 and T25 were expressed as means ± standard error, for 
5-10 experiments and were statistically analysed through one-way ANOVA, 
followed by the Bonferroni post-test. The concentration-response curves and the 
time-course curves were statistically evaluated through two-way ANOVA.  
A level of P < 0.05 was considered to be indicative of a significant statistical 
difference. 
 
 
Results 
The insertion of the  nitrooxymethyl chain in the meta position (as in compounds 
Ar-NO, Ar-NO-α-Me, Benz-NO, Benz-NO-α-Me) or in the para position (as in 
compounds p-Ar-NO, p-Ar-NO-α-Me, p-Benz-NO and p-Benz-NO-α-Me) with 
respect to the carboxylic- (in the benzoic series) or to the hydroxymethyl- function 
(in the benzylic series) was selected in order to investigate the potential influence 
played by steric and/or electronic factors on the NO-releasing properties of these 
compounds. 
Moreover the insertion into the aromatic ring (Ar-NO-2,6-Me2) or into the carbon 
atom of the nitrooxymethyl chain (Ar-NO-α-Me, p-Ar-NO-α-Me and Benz-NO-
α-Me, p-Benz-NO-α-Me) of one (or more) methyl group(s) was also affected 
with the aim of determining the potential influence of these groups on the NO-
releasing kinetics of Ar-NO-α-Me, p-Ar-NO-α-Me, Ar-NO-2,6-Me2,  Benz-NO-
α-Me, p-Benz-NO-α-Me. All the compounds synthesised were tested as 
vasodilator agents on rat aortic rings pre-contracted with a depolarising stimulus 
(KCl 30mM). In this experimental model, all compounds exhibited full or almost 
full vasorelaxing activity. The potency results (expressed as pIC50) and the 
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efficacy (Emax%) of the compounds tested and of reference drug SNP are given 
in Table 2, while the parameters describing the time-course profile of the 
vasorelaxing effect (T25 values), reflecting the NO-release rates, are shown in 
Table 3. As regards  the potency, the pIC50  values were always lower than that 
exhibited by the reference drug sodium nitroprusside (SNP, pIC50 = 8.73), and 
ranged between the lowest pIC50 of 4.83 (recorded for compound Benz-NO-α-
Me) and the highest one of 7.21 (observed for p-Benz-NO). The fact that the 
vasorelaxing effects of all the test compounds and of SNP were almost completely 
abolished by pre-incubation with ODQ (an inhibitor of guanylate cyclase and thus 
of the NO-cGMP pathway), indicated a clear involvement of NO-release in their 
mechanism of action (Fig. 14). Although the potency value in itself was clearly 
influenced by the rate of NO-release, an analysis more closely focused on the 
evaluation of the development of the vasorelaxing effect vs time (through the 
time-course protocol and the T25 parameter) seemed to be a more appropriate 
approach to describe this aspect. Indeed, the T25 parameter reflects the time 
needed to achieve a selected level of vasorelaxing effect (25% of the pre-
contraction by KCl 30 mM) induced by 1 μM of the compounds tested. Thus, the 
T25 parameter could be viewed as an indirect indicator of  the rate of release of 
NO from the drug. As expected, SNP (a well- known rapid NO-releasing agent) 
exhibited a very low T25 value (0.39 min). Two compounds (Benz-NO and p-
Benz-NO)  showed T25 values (0.48 min and 0.45 min, respectively) almost the 
same as to that of SNP. Compound Phen-NO exhibited a T25 value slightly 
higher (2.00 min) than that of SNP, but the two values did not result statistically 
different. All the other compounds proved to be NO-donor agents, possessing a 
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significantly lower rate of NO-release,  with T25 values ranging between 3.84 min 
(p-Ar-NO) and 8.83 min (Ar-NO-α-Me). 1 μM of p-Benz-NO-α-Me determined 
a modest vasorelaxing effect (EM = 26 %), which did not allow the calculation of 
T25. 1 μM of Ar-NO-2,6-Me2 and Benz-NO-α-Me did not evoke any significant 
vasorelaxing effect, indicating that these two compounds were the slowest NO-
donors of the series (Fig. 15). 
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Table 2. The NO-mediated vasorelaxing efficacy of the synthesised compounds and SNP was 
evaluated as the maximal vasorelaxing response, expressed as a percentage (%) of the contractile 
tone induced by 30 mM KCl. The parameter of potency was expressed as pIC50, calculated as 
negative logarithm of the molar concentration of the test compounds, evoking 50% reduction of 
the contractile tone induced by 30 mM KCl. The pIC50 could not be calculated for those 
compounds showing an efficacy parameter lower than 50%.  The parameters of efficacy and 
potency were expressed as means ± standard error, for 5-10 experiments. 
 
 
 
 
 
 
 
 
 
Compound pIC50 Emax % 
SNP 8.73 ± 0.04  100a 
1a 5.80 ± 0.08 78 ± 9 
1b 6.47 ± 0.02 100a 
2a 5.64 ± 0.04 96 ± 2 
2b 5.71 ± 0.02 100a 
3 5.30 ± 0.03 98 ± 2 
4 6.34 ± 0.02 100a 
5 6.26 ± 0.05 100a 
6a 7.03 ± 0.04 100a 
6b 7.21 ± 0.03 100a 
7a 4.83 ± 0.04 91 ± 1  
7b 5.98 ± 0.02 100a 
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Table 3. The time-course profiles of the effects of the synthesised compounds and SNP is 
summarised in the table. EM is the highest vasorelaxing effect (expressed as a % of the contractile 
tone induced by KCl 30 mM) induced by the tested compounds (1 μM). T25 is the time, in min, 
required to reach a level of vasorelaxing effect = 25% of the contractile tone induced by KCl 30 
mM. The parameter of T25 could not be calculated for those compounds, exhibiting an EM lower 
than 25. Some compounds (shown as ineffective) did not exhibit any significant vasorelaxing 
effect, at the concentration 1 μM. 
The values are expressed as means ± standard error, for 5-10 experiments. 
 
 
Compound EM T25 
SNP 98 ± 2 0.39 ± 0.08 
1a 39 ± 8 8.25 ± 0.42 
1b 65 ± 10 3.84 ± 0.48 
2a 42 ± 2 8.83 ± 0.58 
2b 50 ± 7 6.25 ± 0.21 
3 Ineffective - 
4 49 ± 3 4.68 ± 0.33 
5 73 ± 1 2.00 ± 0.27 
6a 90 ± 1 0.48 ± 0.02 
6b 90 ± 4 0.45 ± 0.03 
7a Ineffective - 
7b 26 ± 1 Not Calculable 
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Figure 14. The NO-mediated vasorelaxing efficacy of the synthesised compounds and SNP 
evaluated as the maximal vasorelaxing response, expressed as a percentage (%) of the contractile 
tone induced by 30 mM KCl 
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Figure 15. The time-course profiles of the effects of the synthesised compounds and SNP. 
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Figure 16. Representative examples of the influence of the guanylate cyclase inhibitor ODQ 
1μM on the vasorelaxing effects of the tested compounds: concentration-response curves for 
compounds 1a and 6a, in the presence or in the absence of ODQ. 
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Discussion 
Although this preliminary study has been focused on a limited number of lead 
compounds, some considerations on the structure-activity relationships could be 
hypothesised, thus concerning the influence of slight structural variations on the 
NO-releasing properties of the nitrooxy group.  
As regards the carboxylic derivatives, a comparison of Ar-NO vs p-Ar-NO as 
well as Ar-NO-α-Me vs p-Ar-NO-α-Me showed that the para position ensured a 
more effective NO-release. In particular, p-Ar-NO exhibited levels of potency 
higher than those of Ar-NO; also the T25 value of p-Ar-NO was significantly 
lower than that of Ar-NO, indicating a more rapid release of NO. Although the 
couple of analogues Ar-NO-α-Me and p-Ar-NO-α-Me showed almost equivalent 
levels of potency and efficacy, a more rapid release of NO from p-Ar-NO-α-Me 
was highlighted by its T25 parameter, which was significantly lower than that 
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displayed by Ar-NO-α-Me. As regards  the role played by the insertion of a 
methyl group into the nitrooxymethyl chain, this did not seem to exert any 
significant influence for the couple of meta-substituted  analogues Ar-NO and 
Ar-NO-α-Me, while it seemed to have a negative impact for the para-substituted 
couple p-Ar-NO and p-Ar-NO-α-Me: compound p-Ar-NO-α-Me showed a 
lower level of potency than p-Ar-NO, and, consistently, its NO-release was 
slower. The insertion of two methyl groups into the aromatic ring (Ar-NO-2,6-
Me2) led to a decrease of potency (see Ar-NO-2,6-Me2 vs Ar-NO). Consistently, 
compound Ar-NO-2,6-Me2 (1μM) did not possess any significant vasorelaxing 
effect in the time-course protocol. The replacement of the benzene ring of Ar-NO 
with a pyridine system (Pyr-NO), as well as the replacement of the carboxy 
function of Ar-NO with a hydroxy group (Phen-NO), caused an improvement of 
both the vasorelaxing potency and the rate of NO-release.  The benzylic 
derivatives Benz-NO and p-Benz-NO proved to possess the highest level of 
potency among the compounds tested, and their NO-release rates similar to that of 
SNP. In the benzylic series, the para-substituted compound p-Benz-NO-α-Me 
proved to be more potent NO-donor than the meta-substituted one Benz-NO-α-
Me. However, the positive effect due to this structural feature was not evident for 
the couple of analogues Benz-NO and p-Benz-NO, which exhibited almost 
equivalent levels of pIC50 and T25. The negative influence due to the insertion of 
the methyl group into the nitrooxymethyl chain, already observed in the benzoic 
series, was even more evident in the benzylic ones (see Benz-NO-α-Me vs Benz-
NO and p-Benz-NO-α-Me vs p-Benz-NO). In particular, compound Benz-NO-α-
Me was found to be the less potent among all the compounds tested, and did not 
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exhibit any vasorelaxing effect in the time-course protocol, while compound p-
Benz-NO-α-Me exhibited a poor vasorelaxing effect which did not allow a 
correct evaluation of T25. 
 
Conclusion 
This study aimed to develop some representative NO-donor structures, potentially 
useful as linkers to be added to native drugs, in order to obtain pharmacodynamic 
hybrids. In such hybrids, the presence of the two mechanisms of action was 
clearly the essential condition; however, a correct balancing of the two 
pharmacodynamic properties was another fundamental aspect. In particular, 
depending on the characteristics of the native drug (mechanism of action, 
posology, therapeutic  indications), the release of NO should be correctly 
modulated in order to obtain well-calibrated levels of additive biological effects of 
NO itself. The availability of  different NO-donor linkers possessing different 
NO-releasing rates, thus represented a necessary tool for this purpose. 
The main findings of this work indicate that the shift of the nitrooxymethyl chain 
from the meta-  to the para-position, both in benzoic and in benzylic derivatives 
may significantly influence the NO-donor properties, determining a more 
effective release. Furthermore, the insertion of a methyl group into the 
nitrooxymethyl chain, as well as the presence of two methyl groups on the 
aromatic system, determined a reduction in the rate of NO-release. On the other 
hand, it is reasonable to hypothesise that in a pharmacodynamic hybrid, the NO-
releasing rate of a given NO-donor linker may be influenced by the presence of a 
further molecular portion (i.e. the native drug) linkers alone.  
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CHAPTER 3 
 
 
 
NO-SARTANS: A NEW CLASS OF 
PHARMACODYNAMIC HYBRIDS AS 
CARDIOVASCULAR DRUGS* 
 
*The contents of chapter 3 have been already published: 
 
Breschi M.C., Calderone V., Digiacomo M., Martelli A., Martinotti E., 
Minutolo F., Rapposelli S., Balsamo A. (2004) J. Med. Chem., 47; pp. 5597-
5600. 
 
Breschi M.C., Calderone V., Digiacomo M., Macchia M., Martelli A., 
Martinotti E., Minutolo F., Rapposelli S., Rossello A., Testai L., Balsamo A. 
(2006) J. Med. Chem., 49; pp. 2628-2639. 
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Introduction 
The pharmacotherapy of hypertension involves several different classes of drugs; 
among these, the ones that have the renin-angiotensin system (RAS) as the target 
of their mechanism of action deserve special mention. ACE-inhibitors belong to 
this group, seeing that they act by inhibiting the Angiotensin Converting Enzyme 
(ACE), which is  mainly responsible for the conversion of angiotensin I into 
angiotensin II. The latter is one of the most hypertensive substances in our 
organism: stimulation of the AT1-receptor by angiotensin II determines the 
release of aldosterone, which, by means of a reabsorption of Na+ ions (and 
consequently of liquids) and a loss of K+ ions, provokes hypertension. 
Furthermore, angiotensin II induces a direct vasoconstrictor action, which plays a 
significant role in hypertensive effects. 
ACE is also involved in the mechanism of degradation of many other peptides, 
such as bradykinin. This peptide induces the release of endothelial nitric oxide 
(NO), a factor which plays a key role in the endogenous process of vasodilatation. 
The fact that ACE-inhibitors save bradykinin also leads to a vasorelaxing effect, 
which contributes to the anti-hypertensive action that is mainly due to the lack of 
angiotensin II production (Mombouli and Vanhoutte, 1992; Linz et al., 1995).  
Recent studies seem to indicate the possible existence of bradykinin-potentiating 
effects of ACE-inhibitors, which are independent of the reduction of bradykinin 
hydrolysis; this mechanism was initially demonstrated by using bradykinin 
analogues which were assumed to be ACE-resistant (Auch-Schwelk et al., 1993; 
Danser et al., 2000; Minshall et al., 1997; Minshall et al., 2000; Mombouli et al., 
2002). This hypothesis is based on a “cross-talk” between ACE and bradykinin 
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type 2 (B2) receptors (Marcic et al., 2000) (for example, forming a heterodimer), 
which leads to an up-regulation of the B2 receptor (Minshall et al., 1997), 
probably accompanied by an up-regulation (Marin-Castano et al., 2002) and direct 
activation of bradykinin type 1 (B1) receptors by ACE-inhibitors (Ignjatovic et al., 
2002).  
In view of the above-mentioned reasons, ACE-inhibitors represent a first-choice 
class in hypertension therapy. Furthermore, they also reveal an implication at the 
cardiac level: angiotensin II  inhibits muscular apoptosis, thus provoking 
ventricular hyperplasia, which might aggravate a pre-existent cardiac failure. 
However, ACE-inhibitors also frequently present an adverse side-effect which is 
invalidating in social life, and which drastically reduces the patient’s compliance: 
this is coughing, which is the result of the ability of  ACE-inhibitors to preserve 
bradykinin, a kinin that stimulates the cough-centre, from hydrolysis (Israili and 
Hall, 1992). 
In the last decade, research on drugs which can replace ACE-inhibitors in 
hypertension therapy, without their collateral effects, has led to the discovery of 
sartans (Wexler et al., 1996). Drugs of this class are antagonists of angiotensin II 
at the AT1-receptor and block the action of angiotensin II in a potentially more 
complete way than ACE-inhibitors; as is known, there are other enzymes, besides 
ACE, which are able to contribute to angiotensin II production (Okunishi et al., 
1993). Many comparative clinical trials have shown that sartans do not induce 
coughing because they do not prevent ACE from degrading bradykinin; in the 
past, they were employed when coughing was intolerable in a patient receiving 
therapy with ACE-inhibitors, but nowadays, in view of the evidence presented, 
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sartans can be viewed as a first-choice class of anti-hypertensive drugs (Tanser et 
al., 2000; Zorba Paster et al., 1998). However, sartans lack the enhancement of the 
NO-mediated vasorelaxing effect due to bradykinin preservation. 
The importance of NO lies not only in its vasorelaxing action,  but also in its 
potent inhibition of platelet and neutrophil aggregation in the endothelium 
(Moncada and Higgs, 1993; Loscalzo and Welch, 1995). 
The above-mentioned biopharmacological considerations, together with the 
appreciable results obtained in different classes of NO-releasing drugs, prompted 
us to develop a new class of drugs, by adding a NO-donor group to a sartan 
molecule. This kind of chemical manipulation was likely to give the “native” 
sartan an additional NO-mediated, but bradykinin-independent, vasorelaxing 
effect, thus generating the original class of NO-sartans, pharmacodynamic hybrids 
possessing the properties of a typical AT1-antagonist and of a “slow NO-donor”. 
The new compounds were expected to possess a pharmacodynamic profile very 
similar to that of ACE-inhibitors, but without their bradykinin-mediated adverse 
effects (Breschi et al., 2004). 
An examination of the structures of commercially available sartans showed that 
losartan possesses both the high activity and the molecular features, i.e. the 
presence of an easily esterifiable alcohol group, suitable to provide a template for 
our purpose. As regards the NO-donor moiety, the previously reported (Earl et al., 
2004) m-nitrooxymethylbenzoate (2a, Figure 17) and the 5-nitrooxypentanoate 
(2b, Figure 17) were selected, based on the hypothesis of a different stability 
towards ester bond cleavage, depending on the aliphatic or aromatic nature of the 
compound.  
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Figure 17. Structure of losartan and general structure of the NO-releasing derivatives of losartan  
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The chemical pathway giving access to the final products Los-Ar-NO and Los-
Al-NO is reported in Scheme 3. 
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Key to Scheme 3. aKey: (a) AgNO3, CH3CN, 1h, rt; (b) Losartan, DCC, THF, DMAP, 2h, rt.  
 
                                                                                                                      NO-SARTANS 
 67
m-(chloromethyl)benzoic acid (3a) or 5-chloropentanoic acid (3b) were converted 
into their nitrooxy-derivatives Ar-NO or Al-NO by treatment with silver nitrate in 
acetonitrile at room temperature and in the dark. Condensation of the nitro esters 
(Ar-NO and Al-NO) with losartan in tetrahydrofuran, in the presence of N,N’-
dicyclohexylcarbodiimide (DCC) and a catalytic amount of N,N-
dimethylaminopyridine (DMAP), afforded the corresponding targets compounds 
Los-Ar-NO and Los-Al-NO. 
Pharmacological studies were carried out on the two “pharmacodynamic hybrids” 
Los-Ar-NO and Los-Al-NO, by means of functional tests on vascular tissues, 
usually employed to determine NO-mediated responses (Villarroya et al., 1999) 
and AT1-antagonist activities (Morsing et al., 1999).  
 
Pharmacological procedures (1) 
All the experimental procedures were carried out following the guidelines of the 
European Community Council Directive 86-609. 
In vitro protocols 
The effects of the compounds were tested on isolated thoracic aortic rings of male 
normotensive Wistar rats (250-350 g). After a light ether anaesthesia, rats were 
sacrificed by cervical dislocation and bleeding. 
The aortae were immediately excised, freed of extraneous tissues and the 
endothelial layer was removed by gently rubbing the intimal surface of the vessels 
with a hypodermic needle. Five mm wide aortic rings were suspended, under a 
preload of 2 g, in 20 mL organ baths, containing Tyrode solution (composition of 
saline in mM: NaCl 136.8; KCl 2.95; CaCl2 1.80; MgSO4 1.05; NaH2PO4 0.41; 
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NaHCO3 11.9; Glucose 5.5), thermostated at 37 °C and continuously gassed with 
a mixture of O2 (95%) and CO2 (5%). Changes in tension were recorded by means 
of an isometric transducer (Grass FTO3), connected with an  unirecord 
microdynamometer (Buxco Electronics). 
Evaluation of the NO-releasing properties 
After an equilibration period of 60 minutes, the endothelium removal was 
confirmed by the administration of acetylcholine (ACh) (10 μM) to  KCl (30 
mM)-precontracted vascular rings. A relaxation < 10% of the KCl-induced 
contraction was considered representative of an acceptable lack of the endothelial 
layer, while the organs, showing a relaxation ≥ 10% (i.e. significant presence of 
the endothelium), were discarded. In the first series of experiments, we 
investigated the possible NO-releasing effect of the tested compounds. 
From 30 to 40 minutes after the confirmation of the endothelium removal, the 
aortic preparations were contracted by a single concentration of KCl (30 mM) and 
when the contraction reached a stable plateau, 3-fold increasing concentrations of 
Los-Ar-NO, Los-Al-NO and Ar-NO (1nM-10μM) were added. 
When required by the experimental design, the administration of the tested 
compounds was preceded by the pre-incubation (20 min) of eserin 3μM. 
Preliminary experiments showed that the KCl (30 mM)-induced contractions 
remained in a stable tonic state for at least 40 minutes. 
The same experiments were carried out in the presence of a well-known 
guanylate-cyclase inhibitor: ODQ 1μM which was incubated in aortic 
preparations after the endothelium removal confirmation. 
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Evaluation of the AT1-antagonism 
In the second series of experiments the possible AT1 antagonist activity of the 
selected substances was examined. After the endothelium removal confirmation, 
the tested compound Los-Ar-NO and the reference AT1 antagonist losartan were 
incubated at the concentration of 0.1 μM. 
When required by the experimental protocol, the administration of the tested 
compounds was preceded by the pre-incubation (20 min) of eserin 3μM. 
After an incubation period of 30 minutes, aortic preparations were treated with 
angiotensin II, using 3-fold increasing concentrations (0.1 nM-1 μM). 
Both Los-Ar-NO 0,1μM and Los-Al-NO 0,1μM did not evoke significant 
vasorelaxing effects. Nevertheless, in order to exclude a possible involvement of a 
NO-mediated functional antagonism against the contractile effects of  angiotensin 
II, in previous experiments the study on the AT1-antagonism were carried out in 
the presence of ODQ 1μM. 
These experiments furnished results analogous to those obtained  in the absence of 
ODQ. 
Materials. 
Substances used in the experimental protocols were KCl (Carlo Erba) dissolved 
(3M) in Tyrode solution, acetylcholine chloride (Sigma) dissolved (0.1 M) in 
EtOH 95% and further diluted in bidistillated water. Angiotensin II (Sigma) was 
dissolved (100 μM) and diluted in bi-distilled water. ODQ (Sigma) was dissolved 
(1 mM) in EtOH 95% and further diluted in Tyrode solution. Losartan was 
dissolved (10 mM) in dimetilsulfoxide (DMSO), whereas the following dilutions 
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were dissolved in Tyrode solution. Compounds Los-Ar-NO, Los-Al-NO and Ar-
NO were dissolved (10 mM) in DMSO and further diluted in Tyrode solution. 
All the solutions were freshly prepared immediately before the pharmacological 
experimental procedures. Previous experiments showed a complete 
ineffectiveness of the administration of the vehicles. 
Data analysis.  
The vasorelaxing efficacy was evaluated as maximal vasorelaxing response, 
expressed as a percentage (%) of the contractile tone induced by KCl 30 mM. 
When the limit concentration 10 μM (the highest concentration, which could be 
administered) of the tested compounds did not reach the maximal effect, the 
parameter of efficacy represented the vasorelaxing response, expressed as a 
percentage (%) of the contractile tone induced by KCl 30 mM, evoked by this 
limit concentration. The parameter of potency was expressed as pIC50, calculated 
as negative logarithm of the molar concentration of the tested compounds evoking 
a half reduction of  the contractile tone induced by KCl 30 mM. The pIC50 could 
not be calculated for those compounds showing an efficacy parameter lower than 
50%.  The parameters of efficacy and potency were expressed as mean ± standard 
error, for 5-10 experiments. Student t test was selected as statistical analysis, P < 
0.05 was considered representative of significant statistical differences. 
Experimental data were analysed by a computer fitting procedure (software: 
GraphPad Prism 4.0). 
As regards the AT1-antagonism, the angiotensin II-contracting effects, expressed 
as efficacy and potency, were evaluated as percentage (%) of the previous KCl 
30mM-induced contraction. 
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The parameter of efficacy, corresponding to the maximal contractile effect, was 
calculated as Emax  (mean ± standard error, from 6-12 experiments). 
The parameter of potency of angiotensin II  was calculated as EC50, corresponding 
to the molar concentration of angiotensin II necessary to evoke 1/2Emax. 
The antagonist potency was calculated by Gaddum equation: 
    Kb = B/(DR-1) 
In which: 
Kb represents the antagonist/receptor dissociation constant and B is the antagonist 
concentration. 
While, 
  DR = EC50(in the presence of B)/EC50(in control conditions) 
In vivo protocols. 
The effects of the compounds were also tested on male 10 weeks-old SHRs 
(spontaneous hypertensive rats) (250 g). 
In this protocol the compounds were administered orally (in drinking water) or 
sub-cutaneously  to two set of four groups each composed by three rats. 
Oral administration 
We estimate (on the basis of previous observations) that the daily water intake for 
a single rat was about 50 mL. 
1) The first group (control-group) received the vehicle (DMSO 1%, in drinking 
water). 
2) The captopril-group received captopril 50 mg/Kg/die dissolved in the vehicle. 
3) The losartan-group received losartan 10 mg/Kg/die dissolved in the vehicle. 
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4) The Los-Ar-NO-group received Los-Ar-NO-compound 14.2 mg/Kg/die 
(equimolar to losartan 10 mg/Kg/die). 
Sub-cutaneous administration 
1) The first group (control-group) received the vehicle (DMSO 1%, in dorsal sub-
cutaneous injection, about 0,25-0,30 ml). 
2) The captopril-group received captopril 25 mg/Kg/die dissolved in the vehicle. 
3) The losartan-group received losartan 5 mg/Kg/die dissolved in the vehicle. 
4) The Los-Ar-NO-group received Los-Ar-NO 7.1 mg/Kg/die (equimolar to 
losartan 5 mg/Kg/die). 
Common procedures 
The experimental protocol was divided in a previous period of two weeks, during 
which the rats were daily conditioned to entry and to remain in a containment box. 
After the conditioning time, the animal tails were exposed to a 40 minutes of  
irradiation with an I.R. lamp to determine a vasodilatation of tail vessels. Systolic 
blood pressure values were recorded with the “tail-cuff” method by a BP recorder 
(Ugo Basile 58500). 
All the four groups, were subjected to a four weeks treatment and to three 
measurements (on alternate days, at 9.00 a.m.) in each week.  
Finally we also examined a group of three male normotensive Wistar rats (250g) 
receiving only drinking water; in these animal, after one week of conditioning, 
systolic blood pressure was recorded 3 times (on alternate days, at 9.00 a.m.)  
within only one week. 
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Results and Discussion 
These two compounds induced full vasorelaxing effects (Efficacy = 92 ± 6% and 
95 ± 8%, for Los-Ar-NO and Los-Al-NO, respectively; pIC50 = 5.55 ± 0.09 and 
5.89 ± 0.14, for Los-Ar-NO and Los-Al-NO, respectively) which were strongly 
inhibited by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) 1μM, an 
inhibitor of guanylate cyclase, as to be expected in the case of an NO release 
effect (Efficacy = 34±3% and 23±8%, for Los-Ar-NO and Los-Al-NO, 
respectively; pIC50 values not calculable). 
Also the AT1-antagonist properties of nitrooxy-derivatives Los-Ar-NO and Los-
Al-NO were investigated and compared with those of the reference AT1-
antagonist losartan.  
The concentration-contractile response curve for angiotensin II was shifted 
parallel to the right by Los-Ar-NO and Los-Al-NO, with Kb values of 6 nM and 
16 nM, respectively. Under the same experimental conditions, losartan displayed 
a Kb value of  4 nM, substantially analogous to the value recorded for Los-Ar-
NO and slightly lower than that of Los-Al-NO.  
Compound Los-Ar-NO was selected in order to obtain further information, in an 
attempt to understand the pharmacokinetic steps leading to the pharmacodynamic 
features observed. 
In order to evaluate whether the vasorelaxing properties of Los-Ar-NO are due to 
the release of NO from the whole molecule or from the side chain (Ar-NO), after 
its hydrolytic removal from losartan, the vasorelaxing effects of Ar-NO were 
evaluated by functional tests.  
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Compound Ar-NO showed vasorelaxing effects lower than Los-Ar-NO, both in 
efficacy and in potency (Efficacy = 67 ± 12%; pIC50 =  4.66 ± 0.13).  
This first finding, which seems to indicate that the NO-release from Los-Ar-NO 
is more rapid, and thus that it precedes the possible hydrolysis of the ester link 
between losartan and Ar-NO, is confirmed by the results obtained in the presence 
of eserin (3μM, an inhibitor of esterases) (Gilmer et al., 2002).  
As expected, the presence of the esterase-inhibitor did not alter the vasorelaxing 
effects of Ar-NO (Efficacy = 71 ± 6%; pIC50 =  4.64 ± 0.07); significantly, the 
effects of Los-Ar-NO were not influenced by eserin, either (Efficacy = 91 ± 3; 
pIC50 =  5.37 ± 0.05), confirming that the release of NO from this compound does 
not require previous hydrolytic removal of the side chain. 
An analogous experimental strategy was employed to determine whether the AT1-
antagonist properties of  Los-Ar-NO are due to the whole molecules or to losartan 
(after the hydrolytic removal of the side chains).  
As reported above, the AT1-antagonist potencies of losartan and of Los-Ar-NO 
were quite indistinguishable, and in our opinion, this experimental evidence 
already tended to suggest that the antagonism was exerted by losartan itself, after 
the hydrolytic removal of the side chain, as desired for our purposes.  
The experimental confirmation of this hypothesis was provided by the use of 
eserin: in the presence of this esterase-inhibitor, the antagonist potency of Los-
Ar-NO was dramatically lowered (Kb = 40 nM), while eserin did not influence 
the AT1-antagonist potency of losartan (Kb = 5 nM). 
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These initial functional data suggest that the main aim of this work, i.e. the 
creation of the original pharmacological class of NO-sartan AT1-antagonists/NO-
donor hybrids, has been satisfactorily achieved. 
Furthermore, an “exploratory” in vivo protocol was carried out on Los-Ar-NO, in 
order to obtain a preliminary indication about the possible profile of the anti-
hypertensive action of a compound of this new pharmacological class, in 
comparison with that of an AT1-antagonist and an ACE-inhibitor.  
Consequently, compound Los-Ar-NO, losartan and captopril were administered 
orally or sub-cutaneously to spontaneously hypertensive rats (SHR) for four 
weeks, recording the systolic blood pressure, by the “tail cuff” method (Krege et 
al., 1995).  
The order of magnitude of the oral doses of captopril and losartan was selected on 
the basis of similar experimental protocols, described in literature (Rodrigo et al., 
1997), while Los-Ar-NO was administered at a dose equimolar to that of losartan.  
For sub-cutaneous administration, the doses were reduced by one half. In both 
these sets of experimental conditions, all compounds had practically equivalent 
effects, causing a significant reduction in the systolic pressure, which was lowered 
almost to the levels of reference normotensive animals (Figure 18). 
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Figure 18. Histograms indicate the systolic blood pressure values recorded in the first four weeks 
of oral (A) or sub-cutaneous (B) pharmacological treatment with the vehicle, losartan, captopril 
and Los-Ar-NO. Systolic pressure values of reference normotensive animals are also shown. 
Vertical bars indicate the standard error. 
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In our opinion, this result was of fundamental importance, since the 
ineffectiveness or of a low effectiveness of Los-Ar-NO was considered to be a 
critical factor, capable of invalidating the rational basis of our work.  
In conclusion, the results of in vitro and in vivo studies confirm that these NO-
sartans are actually pharmacodynamic hybrids possessing both the AT1-
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antagonist activity of sartans and the ancillary NO-releasing property of an NO-
donor.   
In addition, they seem to possess anti-hypertensive properties not inferior to those 
of sartans, and it is reasonable to conclude that this new class of drugs strengthens 
the action of the “native” sartans, integrating the satisfactory anti-hypertensive 
effects of the “native” drugs with all the other beneficial roles played by NO in 
the cardiovascular system (Breschi et al., 2004). 
 
 
 
On the basis of the consideration that losartan and its active metabolite (EXP-
3174) (Figure 19) possess both the high activity and the molecular features (i.e. 
the presence of an easily esterifiable group) useful for our purposes, a series of 
new dual molecule, in which losartan itself is linked to different molecular 
portions bearing a nitric ester moiety, were synthesised (Los-Al-NO, Los-Ar-NO, 
Los-p-Ar-NO, Los-Ar-NO-α-Me, Los-p-Ar-NO-α-Me, Los-Ar-NO-2,6-Me2, 
Los-Pyr-NO, Los-NO) (Figure 20). 
 
 
 
 
  
Figure 19. Losartan and its active metabolite: EXP 3174  
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Figure 20. The series of new duel molecule in which losartan is linked to different molecular 
portions bearing a nitric ester moiety. 
 
 
Furthermore, the hybrids in which an aromatic nitric ester is linked to the active 
metabolite of losartan and one in which the nitric ester function is directly linked 
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to losartan itself were synthesised (Exp-Phen-NO, Exp-Benz-NO, Exp-p-Benz-
NO) (Figure 21). 
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Figure 21. The series of new duel molecule in which EXP 3174 is linked to different molecular 
portions bearing a nitric ester moiety. 
 
The “NO-donor linkers” used in this work, present a pyridine system or methyl 
group(s) directly linked to the aromatic systems or to the carbon adjacent to the 
nitric ester function. These linkers were selected on the basis of the hypothesis 
that steric and/or electronic differences, due to their different molecular structures, 
may modulate the rate of NO release and therefore affect the biopharmacological 
responses.  
Pharmacological procedures (2) 
All the experimental procedures were carried out following the guidelines of the 
European Community Council Directive 86-609. 
Exp-Phen-NO
Exp-Benz-NO Exp-p-Benz-NO 
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In vitro vascular protocols 
 
The effects of the compounds were tested on isolated thoracic aortic rings of male 
normotensive Wistar rats (250-350 g). 
After light ether anaesthesia, the rats were sacrificed by cervical dislocation and 
bleeding. 
The aortas were immediately excised and freed from extraneous tissues, and the 
endothelial layer was removed by gently rubbing the intimal surface of the vessels 
with a hypodermic needle. Five-mm-wide aortic rings were suspended, under a 
preload of 2 g, in 20 mL organ baths, containing Tyrode solution (composition of 
saline in mM: NaCl 136.8; KCl 2.95; CaCl2 1.80; MgSO4 7H2O 1.05; NaH2PO4 
0.41; NaHCO3 11.9; Glucose 5.5), thermostated at 37°C and continuously gassed 
with a mixture of O2 (95%) and CO2 (5%). Changes in tension were recorded by 
means of an isometric transducer (Grass FTO3), connected with an unirecord 
microdynamometer (Buxco Electronics). 
After an equilibration period of 60 min, endothelium removal was confirmed by 
the administration of acetylcholine (ACh) (10 μM) to KCl (30 mM)-precontracted 
rings. A relaxation < 10% of the KCl-induced contraction was considered to be 
indicative of an acceptable lack of the endothelial layer, while the organs showing 
a relaxation ≥ 10% (i.e. significant presence of the endothelium) were discarded. 
NO-mediated vasorelaxing effect 
 
From 30 to 40 min after the confirmation of endothelium removal, the aortic 
preparations were contracted by a single concentration of KCl (30mM), and when 
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the contraction reached a stable plateau, 3-fold increasing concentrations of the 
test substances (1nM-100μM) were added. 
Preliminary experiments showed that the KCl (30 mM)-induced contractions 
remained in a stable tonic state for at least 40 min. 
The same experiments were carried out in the presence of a well-known 
guanylate-cyclase inhibitor; ODQ 1μM, which was incubated in aortic 
preparations after confirmation of endothelium removal. 
 
AT1 antagonist activity 
From 30 to 40 min after confirmation of endothelium removal, the test 
compounds were incubated at a concentration of 0.1μM. As the concentration 
0.1μM of compounds Los-Ar-NO and Los-p-Ar-NO already induced a 
significant vasorelaxing effect, Los-Ar-NO and Los-p-Ar-NO were incubated 
together with ODQ 1μM, in order to avoid any influence of the NO-mediated 
effects on the contractile response evoked by AII. 
Then, after an incubation period of 20 or 60 min, aortic preparations were treated 
with AII, using 3-fold increasing concentrations from 0.1 nM-1μM. 
In parallel sets of experiments, the control concentration-contractile response 
curves for AII were obtained after the pre-incubation of only the vehicle (or 
vehicle and ODQ 1μM for Los-Ar-NO and Los-p-Ar-NO). 
 
Time-course of NO-mediated vasorelaxing effect 
From 30 to 40 min after confirmation of endothelium removal, aortic preparations 
were contracted with a single concentration of KCl 30mM, and after a stable 
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plateau had been reached, a single concentration (1μM) of the compounds was 
added. The vasorelaxing effect of the added compounds was monitored for 50 
min. 
 
Data analysis 
The vasorelaxing efficacy was evaluated as the maximal vasorelaxing response, 
expressed as a percentage (%) of the contractile tone induced by KCl 30mM. 
When the limit concentration 100 μM (the highest concentration that could be 
administered) of the tested compounds did not reach the maximal effect, the 
parameter of efficacy represented the vasorelaxing response, expressed as a 
percentage (%) of the contractile tone induced by KCl 30mM, evoked by this limit 
concentration. The parameter of potency was expressed as pIC50, calculated as the 
negative logarithm of the molar concentration of the test compounds, evoking a 
50% reduction of the contractile tone induced by KCl 30mM. The pIC50 could not 
be calculated for those compounds showing an efficacy parameter lower than 
50%. The parameters of efficacy and potency were expressed as means ± standard 
error, for 5-10 experiments. Student t test was selected for statistical analysis, and 
P < 0.05 was considered to be indicative of a significant statistical difference. 
Experimental data were analysed by a computer fitting procedure (software: 
GraphPad Prism 4.0). 
As regards the AT1-antagonism, the AII-contracting effects, expressed as efficacy 
and potency, were evaluated as a percentage (%) of the previous KCl 30mM-
induced contraction. 
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The parameter of efficacy, corresponding to the maximal contractile effect, was 
calculated as Emax (mean ± standard error, from 6-12 experiments). 
The parameter of potency of AII was calculated as EC50, corresponding to the 
molar concentration of AII necessary to evoke 1/2Emax. 
The antagonist potency was calculated by Gaddum’s equation: Kb=B/(DR-1), in 
which Kb represents the antagonist/receptor dissociation constant and B is the 
antagonist concentration, while DR=EC50(in the presence of B)/EC50(in control 
conditions). 
 
In vitro cardiac protocols 
Adult male Wistar rats (260-350 g) were randomly assigned to one of three 
groups. In the first group (n=5), animals were treated with an intra-peritoneal (i.p.) 
injection (about 0.3 mL) of compound Losartan (15.0 mg/Kg), the second group 
(n=5) was treated with the equimolar dose of compound Los-Ar-NO (21.3 mg/Kg 
i.p.), and the third group (n=5) received the vehicle (DMSO).  
After 2 h, all the animals were anaesthetised with sodium pentobarbital (100 
mg/Kg i.p.) and heparinised (100 UI i.p.) to prevent blood clotting. After the 
opening of the chest, the hearts were quickly excised and placed in a 4°C Krebs 
solution (composition mM: NaHCO3 25.0, NaCl 118.1, KCl 4.8, MgSO4 1.2, 
CaCl2.2H2O 1.6, KH2PO4 1.2, glucose 11.5) equilibrated with 95% O2 5% CO2, to 
stop the contraction and to reduce oxygen consumption. Rapidly, the ascending 
aorta was cannulated and hearts mounted on a Langendorff apparatus, then the 
perfusion with Krebs solution (thermostated at 37°C and continuously bubbled 
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with a gas mixture of 95% O2 and 5% CO2) was started at constant pressure (70-
80 mmHg). The above procedure was executed within 2 min.  
A water-filled latex balloon connected to a pressure transducer (Bentley Trantec, 
mod 800) was introduced into the left ventricle via the mitral valve and the 
volume was adjusted to achieve a stable left ventricular end-diastolic pressure of 
5-10 mmHg during initial equilibration. The heart rate (HR) and left ventricular 
developed pressure (LVDP) were monitored by a Biopac system (California, 
USA) and the parameter of Rate Pressure Product (RPP) was calculated as RPP = 
HR x LVDP. 
The coronary flow (CF) was measured volumetrically and was expressed as mL of 
the perfusate collected in 1 min. 
After a 30 min equilibration pre-ischaemic period, the hearts were subjected to 30 
min of global ischaemia (no flow), then they were reperfused for 30 min 
(reperfusion period). 
The functional parameters of RPP and CF were measured before the global 
ischaemia and at 5 min intervals during the reperfusion time. The values of post-
ischaemic RPP and of post-ischaemic CF, recorded in the reperfusion time, were 
reported as a percentage of the respective pre-ischaemic values. Hearts showing 
severe arrhythmia were excluded from the experiments. 
 
In vitro anti-platelet activity 
Male Wistar rats (250-300g) were anaesthetised with sodium pentobarbital 
(100mg/Kg, i.p.), the chest was opened and the blood (7-10 mL) was obtained 
through intracardiac puncture. 
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Blood was collected into 5 mL plastic syringes containing 3.8% sodium citrate 
(1:9 v/v) and then centrifuged. 
Human venous blood was obtained from healthy volunteers who had not taken  
any drug for at least two weeks. Volunteers were informed that blood samples 
were obtained for research purposes and that their privacy would be protected.  
Platelet-rich plasma (PRP) was obtained by centrifugation at 80g for 40 min at 
room temperature. Then the top layer, PRP, was removed while the residual blood 
sample was centrifuged at 1550g  for 25 min in order to obtain platelet-poor 
plasma (PPP). The PRP platelet number was adjusted at about 6 × 105 
platelets/μL, through dilution with normal saline (NaCl 0.9%). 
Platelets aggregation was determined, in diluted PRP, by an optical method, using 
a turbidimetric aggregometer (Elvi 840, Milan). In the aggregometer, contents of 
cuvettes (500μL) were maintained at 37°C and stirred constantly at 1000 r.p.m. 
Changes in light transmission through the diluted PRP and PPP were used for 
calibration, and represent minimum (0%, no aggregation) and maximum (100%, 
full aggregation) light transmission, respectively. 
In preliminary experiments concentration-response curves to the aggregating 
agent (ADP) were obtained, and the 5μM ADP concentration was selected. 
Aggregation % was recorded as increased light transmission after the addition of 
the aggregating stimulus and has been expressed as mean ± standard error, from 
groups of 10-12 samples (the samples of each group were collected from at least 3 
different individuals). The inhibitory effects of compounds Losartan (100μM) 
and Los-Ar-NO (100μM) on the ADP 5μM-induced aggregation were evaluated. 
The tested compounds were added 2 min before the administration of ADP 5μM. 
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Control responses were obtained in the presence of drug vehicle only (DMSO). 
The final concentration of DMSO was 0.5%.  
 
In vivo protocols 
The effects of the compounds were also tested on male 10-week-old SHRs 
(spontaneously hypertensive rats), (250g). 
In this protocol, the test substances were administered orally, in drinking water, or 
sub-cutaneously, to two sets of four groups, each composed of three rats. The 
order of magnitude of the oral doses of captopril and losartan was selected on the 
basis of similar experimental protocols, described in literature (Rodrigo et al., 
1997). Los-Ar-NO was administered at a dose equimolar to that of losartan. For 
sub-cutaneous administration, the doses were reduced by one-half. 
Oral administration 
We estimated that the daily water intake for a single rat was about 50 mL. 
1) The first group (control-group) received the vehicle (DMSO 1%, in drinking 
water). 
2) The captopril-group received captopril 50mg/Kg/die dissolved in the vehicle. 
3) The losartan-group received losartan 10mg/Kg/die dissolved in the vehicle. 
4) The Los-Ar-NO-group received Los-Ar-NO 14.2 mg/Kg/die (equimolar to 
losartan 10mg/Kg/die). 
Sub-cutaneous administration 
1) The first group (control-group) received the vehicle (DMSO 1%, in a dorsal 
sub-cutaneous injection, about 0.25-0.30 mL). 
2) The captopril-group received captopril 25 mg/Kg/die dissolved in the vehicle. 
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3) The losartan-group received losartan 5mg/Kg/die dissolved in the vehicle. 
4) The Los-Ar-NO-group received Los-Ar-NO 7.1 mg/Kg/die (equimolar to 
losartan 5mg/Kg/die). 
Common procedures 
The experimental protocol was divided: after an initial period of two weeks, 
during which the rats were daily conditioned to enter and to remain in a 
containment box, the animals’ tails were exposed to 40 minutes of irradiation with 
an IR lamp to determine a vasodilation of tail-vessels. Systolic blood pressure 
values were recorded with the “tail-cuff” method by a BP recorder (Ugo Basile 
58500). 
All the four groups were subjected to four weeks’ treatment and to three 
measurements a week (on alternate days).  
Finally, we also examined a group of three male normotensive Wistar rats (250g) 
which received only drinking water; in these animals, after one week of 
conditioning, systolic blood pressure was recorded 3 times in only one week. 
At the end of all the in vivo procedures, we evaluated cardiac and ventricular 
hypertrophy in SHRs: we recorded the body weight of each animal and then, after 
light ether anaesthesia, rats were sacrificed by cervical dislocation and bleeding. 
The whole hearts were immediately excised, freed from extraneous tissues and 
then subdivided into left and right ventricles and atria. After rapid but careful 
washing and drying, we recorded the weights of left ventricle, right ventricle and 
atria, and we calculated the following ratios, as described in literature (Lassila et 
al., 2003) 
• Heart weight/body weight (g/Kg) 
                                                                                                                      NO-SARTANS 
 88
• Left ventricle weight/body weight (g/Kg) 
• Right ventricle weight/body weight (g/Kg) 
The same ratios were also calculated in the sample (n=3) of normotensive 
animals, not submitted to any pharmacological treatment. 
 
Materials 
The substances used in the pharmacological experimental protocols were KCl 
(Carlo Erba) dissolved (3M) in Tyrode solution, Acetylcholine chloride (Sigma) 
dissolved (0.1 M) in EtOH 95% and further diluted in twice-distilled water; 
Angiotensin II (Sigma) was dissolved (1 mM) in twice-distilled water and then 
diluted; 
ODQ (Sigma) was dissolved (1 mM) in EtOH 95% and further diluted in Tyrode 
solution; 
losartan was dissolved (10 mM) in DMSO, whereas the following dilutions were 
dissolved in Tyrode solution.  
The reference NO-releasing drug SNP (Sigma) was dissolved (10 mM) in DMSO 
and then diluted in Tyrode solution. Sodium pentobarbital (Sessa) was dissolved 
in twice-distilled water. Heparin Vister was purchased by Pfizer as injectable 
preparation. ADP (Sigma) was dissolved in twice-distilled water. 
All the synthesised compounds were dissolved (10 mM) in DMSO and further 
diluted in Tyrode solution. 
All the solutions were freshly prepared immediately before the pharmacological 
experimental procedures. Previous experiments showed a complete 
ineffectiveness of the administration of the vehicles. 
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Pharmacological results 
NO-mediated vasorelaxing activity 
All the tested compounds (Los-Al-NO, Los-Ar-NO, Los-p-Ar-NO, Los-p-Ar-
NO-α-Me, Los-Ar-NO-2,6-Me2, Los-Pyr-NO, Los-NO), with the only exception 
of Los-Ar-NO-α-Me which exhibited only a partial efficacy, evoked 
concentration-dependent vasorelaxing responses, with full efficacy, on rat aortic 
rings pre-contracted by KCl 30 mM (Table 4). 
Compound pIC50 Emax % 
Los-Al-NO 6.07 ± 0.11 100 
Los-Ar-NO 6.56 ± 0.08  100 
Los-p-Ar-NO 7.18 ± 0.03 100 
Los-Ar-NO-α-Me Not calculable 47 ± 1 
Los-p-Ar-NO-α-Me 5.11 ± 0.03 100 
Los-Ar-NO-2,6-Me2 4.49 ± 0.02 100 
Los-Pyr-NO 4.91 ± 0.06 100 
Exp-Phen-NO 5.22 ± 0.08 100 
Exp-Benz-NO 6.18 ± 0.03 100 
Exp-p-Benz-NO 6.56 ± 0.02 100 
Los-NO 4.82 ± 0.07 100 
 
Table 4. The NO-mediated vasorelaxing efficacy of the synthesised compounds was evaluated as 
the maximal vasorelaxing response, expressed as a percentage (%) of the contractile tone induced 
by KCl 30 mM. The parameter of potency was expressed as pIC50, calculated as the negative 
logarithm of the molar concentration of the test compounds, evoking 50% reduction of the 
contractile tone induced by KCl 30 mM. The pIC50 could not be calculated for those compounds 
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showing an efficacy parameter lower than 50%. The parameters of efficacy and potency were 
expressed as means ± standard error, for 5-10 experiments. 
 
 All these responses were significantly antagonised by the inhibition of guanylate 
cyclase, achieved by the administration of 1-H-[1,2,4]-oxadiazole-[4,3-a]-
quinoxalin-1-one (ODQ) 1μM, thus indicating that the vasorelaxing effect was 
due to the release of NO from the hybrid drugs, and therefore to the triggering of 
the NO-cGMP pathway. 
In particular, compounds Exp-Benz-NO, Exp-p-Benz-NO showed a vasorelaxing 
activity with potency parameters almost comparable with those exhibited by Los-
Al-NO and Los-Ar-NO. Compound Los-p-Ar-NO showed the strongest 
vasorelaxing activity, with a potency parameter (pIC50) higher than those 
exhibited by the previously described pioneer compounds Los-Al-NO and Los-
Ar-NO (Figure 22A/B). 
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Figure 22A.  Concentration-vasorelaxing effect curves of hybrid derivatives of Losartan. X Axis 
: Logarithm of the molar concentration of the test compounds; Y Axis: vasorelaxing effect, 
expressed as a percentage (%) of the contractile tone induced by KCl 30 mM; Bars: standard 
errors. 
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Figure 22B.  Concentration-vasorelaxing effect curves of hybrid derivatives of EXP 3174. X 
Axis : Logarithm of the molar concentration of the test compounds; Y Axis: vasorelaxing effect, 
expressed as a percentage (%) of the contractile tone induced by KCl 30 mM; Bars: standard 
errors. 
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In comparison with Los-Al-NO and Los-Ar-NO, compounds Los-p-Ar-NO-α-
Me and Exp-Phen-NO showed a moderate decrease in the pIC50 values (about 
one order of magnitude), while Los-Ar-NO-2,6-Me2, Los-Pyr-NO and Los-NO 
exhibited a greatly reduced potency index (about two orders of magnitude). 
Finally, compound LosAr-NO-α-Me showed only partial vasorelaxing efficacy 
(< 50 %, at the highest concentration administered), which did not allow the 
calculation of the potency index. 
The experimental results emerging from the time-course protocols are fully 
consistent with the pIC50 values recorded with the cumulative concentration-
response curves, thus indicating that the differences in the potency are linked to 
different rates of NO release. As expected, the concentration of 1 μM of 
compounds LosAr-NO-α-Me, Los-p-Ar-NO-α-Me, Los-Ar-NO-2,6-Me2, Los-
Pyr-NO, Exp-Phen-NO and Los-NO evoked modest vasorelaxing responses (< 
25%) in this experimental protocol, because of their low potency indexes. 
Compound Los-Ar-NO (1 μM) determined a reduction to approximately one half 
of the contractile tone of the vessels (Figure 23). The most potent compound Los-
p-Ar-NO (1 μM) caused an almost complete vasorelaxing effect (Figure 23). 
Although compounds Exp-Benz-NO, Exp-p-Benz-NO showed vasorelaxing 
potencies lower than that of Los-p-Ar-NO, their time-course vasorelaxing 
profiles were similar to that of Los-p-Ar-NO (Figure 23). Moreover, a 
comparison of the time-course vasorelaxing effects of the synthesised compounds 
with those of sodium nitroprusside (SNP, a rapid NO-donor selected as a 
reference drug) showed that the release of NO by NO-sartans is a slow process 
(Figure 23). 
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Figure 23. Representative time-course profile of the vasorelaxing effect evoked by the 
concentration 1μM of selected test compounds. Compounds presenting a final vasorelaxing effect 
lower than 25% are not shown. X Axis : time expressed in minutes. Y Axis: vasorelaxing effect, 
expressed as a percentage (%) of the contractile tone induced by KCl 30 mM; Bars: standard 
errors. 
 
AT1-antagonist activity 
After 20 min of incubation, compounds Los-p-Ar-NO and Los-Pyr-NO exhibited 
AT1-antagonist properties, with potency parameters (Kb) in the nanomolar range, 
similar to those shown by the pioneer drugs Los-Al-NO and Los-Ar-NO and to 
that of the reference antagonist losartan  (Table 5). 
In these experimental conditions, compounds Los-Ar-NO-α-Me, Los-p-Ar-NO-
α-Me, Los-Ar-NO-2,6-Me2 and Los-NO failed to exert any significant 
antagonism, while a prolonged incubation time (60 min) allowed compounds Los-
Ar-NO-α-Me, Los-p-Ar-NO-α-Me and Los-NO to exhibit a significant AT1-
antagonism, with potency indexes which again reached the nanomolar range 
(Table 5). As regards compounds Exp-Phen-NO and Exp-Benz-NO, Exp-p-
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Benz-NO, hybrid derivatives of  EXP3174, after a “brief” incubation time (20 
min) only compound Exp-Phen-NO (0.1 μM) determined an almost complete 
abolition of the vasocontractile effects of angiotensin II, exhibiting the profile of 
insormountable antagonism typical of EXP3174 (Table 5). Compounds Exp-
Benz-NO, Exp-p-Benz-NO were uneffective after a “brief” incubation time and 
required a prolonged one (60 min) to release the “native” drug EXP3174 and thus 
to exert an insormountable antagonism (Table 5).  
Compounds Kb (20min) Kb (60min) 
Losartan 4nM 9nM 
EXP 3174 Insormountable* Insormountable* 
Los-Al-NO 16nM N.T. 
Los-Ar-NO 6nM 10nM 
Los-p-Ar-NO 19nM N.T. 
Los-Ar-NO-α-Me N.A. 12nM 
Los-p-Ar-NO-α-Me N.A. 8nM 
Los-Ar-NO-2,6-Me2 N.A. N.T. 
Los-Pyr-NO 8nM N.T. 
Exp-Phen-NO Insormountable* N.T. 
Exp-Benz-NO N.A. Insormountable* 
Exp-p-Benz-NO N.A. Insormountable* 
Los-NO N.A. 3nM 
 
Table 5. Antagonist potency values of the test compounds (expressed as Kb) after a “brief” (20 
min) and a “longer” (60 min) period of incubation. N.A. (no activity) means that the compound 
has no AT1-antagonist properties after a “brief” period of incubation. N.T. (not tested) means that 
the compound which showed AT1-antagonist properties after 20 min was not tested in the 60 min 
incubation protocol. The asterisk (*) indicates that the compound exhibited an insormountable 
antagonist feature, typical of non-reversible receptor antagonists, such as EXP3174. 
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Although the reference AT1 antagonists Losartan and EXP3174, as well as the 
hybrid derivative Los-Ar-NO, showed the antagonist properties after 20 min of 
incubation time (“brief” period), they were also incubated for 60 min (prolonged 
incubation). Their antagonist profiles recorded in these latter experimental 
conditions were almost equivalent to those observed after the “brief” incubation 
time (Table 5). 
 
Cardiac anti-hypertrophic effects 
As widely reported in international literature (Lassila et al., 2003), the 
spontaneously hypertensive rats used in this study previously reported (Breschi et 
al., 2004) showed a significant cardiac hypertrophy, almost exclusively due to an 
increased mass of the left ventricle (Figure 24). 
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Figure 24. The histograms represent the ratios expressed in g/Kg. 
[H] indicates the ratio value between the whole heart weight and the rat body weight 
[L] indicates the ratio value between the left ventricle weight and the rat body weight 
[R] indicates the ratio value between the right ventricle weight and the rat body weight. 
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Vertical bars indicate the standard error. The asterisk (*) indicates significant statistical differences 
between a treated group and the corresponding vehicle group. The circle (°) indicates a significant 
statistical difference between the normotensive group and the vehicle group. 
 
As expected, the administration of the AT1-antagonist losartan or the ACE-
inhibitor captopril led to a reduction in the left ventricle mass and, consequently, 
in the overall cardiac mass, which went down to the levels recorded in the 
normotensive animals. In the same type of experiment, compound Los-Ar-NO 
exhibited anti-hypertrophic effects, which proved to be very similar to those 
shown by losartan  and captopril (Figure 24). 
 
Anti-ischaemic effects 
Losartan and compound Los-Ar-NO were tested on an experimental model of 
cardiac ischaemia/reperfusion.  
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Figure 25. Parameters of RPP and CF, recorded during the 30 min of post-ischaemic period and 
expressed as a % of the respective values observed in the pre-ischaemic period, on Langendorff 
perfused hearts from rats pre-treated with vehicle, losartan or compound Los-Ar-NO. The vertical 
bars indicate the standard error. 
 
The ischaemic injury, evaluated with the functional parameters of post-ischaemic 
inotropism (evaluated as Rate-Pressure Product, RPP) and coronary flow (CF), 
was not reduced by losartan. While compound Los-Ar-NO induced a marked 
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improvement of the two parameters: the RPP parameter reached an almost 
complete recovery of the levels recorded in the pre-ischaemic time and the CF 
recorded in the reperfusion time was almost two-fold higher than that recorded in 
the pre-ischaemic period (Figure 25). 
 
Anti-platelet effects 
Adenosine diphosphate (ADP) 5μM determined on rat platelet rich plasma (PRP) 
a significant platelet aggregation (67 ± 1 %; Fig. 26A). The effect of ADP was 
partially reduced by losartan (50 ± 5 %; Fig. 26A). Compound Los-Ar-NO 
caused a more pronounced anti-platelet activity, determining an about half-
reduction of the aggregating effects of ADP (41 ± 4 %; Fig. 26A). This inhibition 
of aggregation by Los-Ar-NO is more evident in human PRP in which ADP 5μM 
determined an aggregation of 27 ± 1 % (Fig. 26B) not significantly inhibited by 
losartan (20 ± 4 %; Fig.26B) but significantly inhibited by Los-Ar-NO (12 ± 1 %; 
Fig. 26B). 
                                                                                      
+ Vehicle + Losartan + Los-Ar-NO
0
10
20
30
*
*
B
A
gg
re
ga
tio
n 
%
 
Figure 26. The histograms represent the aggregating effects induced by ADP 5μM on rat (A) and 
human (B) platelet rich plasma (PRP), in the presence of the vehicle, losartan or compound Los-
Ar-NO. The vertical bars indicate the standard error. 
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Discussion 
 
The two reported pioneer compounds (Los-Al-NO and Los-Ar-NO) showed both 
NO-releasing effects and AT1-antagonist properties. In particular, compounds  
Los-Al-NO and Los-Ar-NO produced vasorelaxing effects, showing potency 
indexes (pIC50) in the micromolar range. These vasorelaxing effects were shown 
to be due to the release of NO, because they were antagonised by the guanylate 
cyclase inhibitor ODQ (1μM). 
Both these compounds exhibited also the desired AT1-antagonist effects. As the 
hybrid compound Los-Ar-NO exerted AT1-antagonist effects in eserin-free 
conditions, while the presence of eserin (esterase inhibitor) dramatically reduced 
this antagonism, it was clear, as previously demonstrated, that the AT1-blocking 
activity was due to the hydrolytic cleavage of the side chain and the release of the 
“native” losartan. Consistently, the AT1-antagonist properties of Los-Al-NO  and 
Los-Ar-NO (Kb = 16 nM and 6 nM, respectively) were slightly lower (Los-Al-
NO) than, or substantially equivalent (Los-Ar-NO) to, those shown by losartan 
itself ( Kb = 4 nM).  
This experimental evidence demonstrated the concrete possibility of developing 
such a class of pharmacodynamic hybrids.  
As regards hybrid “dual” molecules, the presence of both the desired mechanisms 
of action represents the first necessary condition. Another fundamental aspect 
concerns the correct balancing of the two pharmacodynamic properties, in order to 
obtain drugs that can profitably be applied in therapy. In particular, the NO 
release from an NO-sartan should be correctly modulated in order to strengthen 
the anti-hypertensive activity of the native drug and, in particular, to ensure 
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additional desired beneficial cardiovascular effects such as the antiplatelet and 
anti-ischaemic ones, without exasperating the negative effects, such as an 
excessive hypotensive response. According to this view, the NO-modulated 
vasorelaxing effects should be moderate, because the additional contribution of a 
strong vasodilator activity seems to be inessential (or even deleterious) for drugs 
already possessing a good anti-hypertensive efficacy, such as sartans.  
Therefore, in order to develop a representative collection of prototypical NO-
sartans differing from each other in their variable NO-releasing rates, compound 
Los-Ar-NO underwent various structural modifications of the NO-donor moiety. 
The first step consisted of the direct insertion of the nitric ester on the hydroxyl 
group of losartan. The target compound Los-NO exhibited a low vasorelaxing 
potency and, consistently, the administration of Los-NO at a concentration of 
1μM did not produce any vasorelaxing effect in the time-course protocols. This 
can be explained by the hypothesis of a very slow release of NO and, 
consequently, of free losartan from the hybrid. This hypothesis seems to be 
confirmed by the observation of the AT1-antagonism of this compound. Indeed, 
Los-NO did not antagonise the AT1 receptor after a “brief” incubation (20 min), 
indicating that such a short period does not allow the hybrid to release losartan. 
On the contrary, a longer incubation time (60 min) allowed the compound to reach 
a losartan-like AT1-antagonism. Moreover, the unsatisfactory NO-releasing 
properties of Los-NO suggested the need for the presence of a “linker” moiety 
between the native sartan and the nitrate ester, ensuring a significant, albeit 
modulated, release of NO. Therefore, a series of NO-releasing side chains, 
analogues of Ar-NO, were synthesised. Preliminary experiments demonstrated 
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that all these side chains showed ODQ-sensitive vasorelaxing effects due to the 
release of NO, with potency indexes (IC50) ranging around the micromolar order 
of magnitude.  
The pyridine compound Los-Pyr-NO, with the heterocycle ring replacing the 
benzene one of Los-Ar-NO, showed a significant decrease in the vasorelaxing 
potency, and a consistent lack of vasoactive effects in the time-course protocol. 
Compound Los-Pyr-NO exhibited a losartan-like AT1-antagonist potency after 
the “brief” incubation time (20 min), indicating a rapid hydrolytic cleavage of the 
side chain and a rapidly exhaustive release of free losartan. 
The introduction of (a) methyl group(s) on the nitrooxymethyl chain carbon or on 
the benzene ring of Los-Ar-NO, giving compounds Los-Ar-NO-α-Me and Los-
Ar-NO-2,6-Me2 respectively, determined a negative impact on the NO-releasing 
properties. Indeed, the vasorelaxing potencies fell dramatically both in Los-Ar-
NO-α-Me (pIC50 not calculable because of the vasodilator efficacy < 50%) and in 
Los-Ar-NO-2,6-Me2. Of course, these two compounds were devoid of any 
vasorelaxing effects in the time-course protocols. Although the lack of a 
significant NO-releasing property makes these two compounds uninteresting for 
further development, their AT1-antagonist profile was also evaluated. Neither of 
the compounds exhibited any significant AT1-antagonism after the “brief” 
incubation time (20 min). Compound Los-Ar-NO-α-Me was arbitrarily selected 
(as representative of both of them) for the evaluation of the AT1-antagonism after 
a longer incubation period (60 min), and in these experimental conditions it 
showed an AT1-blocking potency similar to that shown by losartan. This evidence 
seems to indicate that the hydrolytic cleavage of the side chain, allowing the 
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release of free losartan, could be slowed down by the presence of (a) methyl 
substituent(s). 
The shift of the nitrooxymethyl chain from the meta position of Los-Ar-NO to the 
para position of Los-p-Ar-NO, led to a substantial increase of vasorelaxing 
potency. This vasorelaxing activity was ODQ-sensitive, indicating the 
involvement of the release of NO. Consistently, Los-p-Ar-NO also exhibited the 
highest vasorelaxing effect in the time-course protocol, leading to an almost 
complete recovery of the basal tone of the vascular smooth muscle pre-contracted 
by KCl. However, it is noteworthy that a comparison of the time-course profiles 
of the vasorelaxing effects induced by Los-p-Ar-NO and by sodium 
nitroprusside, demonstrated that Los-p-Ar-NO can be considered as a slow NO-
donor. After the “brief” incubation time (20 min), Los-p-Ar-NO demonstrated a 
clear AT1-antagonism, although it showed a potency index slightly lower than 
that of losartan, probably because of a significant, but not yet complete, release of 
the free “native” drug.  
As clearly emerged from the comparison between the two analogues Los-Ar-NO 
and Los-Ar-NO-α-Me, also the introduction of a methyl substituent on the 
nitrooxymethyl chain of Los-p-Ar-NO, giving the analogue Los-p-Ar-NO-α-Me, 
caused a slowing down of the NO-releasing rate, represented by the lowering of 
the potency index. The time-course protocol revealed a weak vasorelaxing effect 
induced by Los-p-Ar-NO-α-Me 1μM. As observed in the couple of analogues 
Los-Ar-NO and Los-Ar-NO-α-Me, also for the couple Los-p-Ar-NO and Los-p-
Ar-NO-α-Me the presence of the methyl group seems to cause a delayed 
hydrolytic cleavage of the side chain and a delayed release of free losartan, 
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because the AT1-antagonism was not recorded after the “brief” incubation (20 
min), but it appeared after 60 min of incubation, with losartan-like levels of 
potency. 
Finally, the investigation of the impact due to the “inversion” of the ester bond 
linking the side chain to the sartan, was performed by studying Exp-Phen-NO 
and Exp-Benz-NO and Exp-p-Benz-NO. These compounds exhibited a 
significant vasorelaxing potency. In particular, the vasorelaxing potency of 
compound Exp-Phen-NO, a phenolic ester, was lower than that of Los-Ar-NO. 
The insertion of a benzylic linker (Exp-Benz-NO and Exp-p-Benz-NO) led to a 
significant increase of the potency parameters, which resulted almost similar to 
that exhibited by Los-Ar-NO. Consistently with what observed with the couples 
of analogues discussed above (Los-Ar-NO vs Los-p-Ar-NO and Los-Ar-NO-α-
Me vs Los-p-Ar-NO-α-Me), the shift of the nitrooxymethyl chain from the meta 
position to the para position (Exp-Benz-NO vs Exp-p-Benz-NO) caused, again, 
an increase of the vasorelaxing potency. As expected, the vasorelaxing effect of 
Exp-Phen-NO, at a concentration of  1μM, was negligible in the time-course 
protocol. While compounds Exp-Benz-NO and Exp-p-Benz-NO showed time-
course vasorelaxing profiles similar to that of Los-p-Ar-NO. 
As regards the AT1-antagonism, Exp-Phen-NO showed a high antagonist 
effectiveness after the “brief” incubation time (20 min), indicating a relatively 
rapid cleavage of the “inverse” phenolic ester and a complete release of active 
Exp3174. The presence of the “inverse” benzylic ester of Exp-Benz-NO and 
Exp-p-Benz-NO caused a slowing down of the hydrolytic cleavage; indeed, 
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compounds Exp-Benz-NO and Exp-p-Benz-NO showed significant AT1-
antagonism (due to the release of Exp3174) only after 60 min of incubation time.  
As the rational strategy leading to the development of a generic pharmacodynamic 
hybrid aims to confer additional positive properties, without decreasing the 
fundamental profile of effectiveness of the native drug, it is evident that such a 
hybrid must fit in with the “golden paradigm”: it must not  show any reduction of 
the basic pharmacological properties of the native drug itself. As far as sartans are 
concerned, this pharmacological class is considered as fully satisfactory for the 
treatment of important cardiovascular diseases, such as hypertension and/or 
cardiac hypertrophy. Consequently, the first inevitable step in the development of 
NO-sartans is a demonstration that, in such hybrids, the presence of the NO-donor 
property does not compromise (by possible pharmacodynamic interactions and/or 
chemical influences) the effectiveness of the native drugs, as regards their main 
therapeutic indications. In other words, the possible addition of new properties 
(for example, antiplatelet and anti-ischaemic effects, expected as a result of the 
release of NO) is subordinate to the maintenance of intact (or improved) anti-
hypertensive and anti-hypertrophic effects, since their reduction can undermine 
the rational basis for the development of this novel class of cardiovascular drugs. 
Consequently, in the light of the impossibility of identifying the NO-sartan 
exhibiting the optimal balance between the two pharmacodynamic properties, 
compound Los-Ar-NO was selected as a representative NO-sartan for further 
preliminary investigation, since it presented intermediate NO-releasing rate levels, 
among the various NO-sartans synthesised in this work. As previously reported 
(Breschi et al., 2004), the chronic oral or subcutaneous administration of Los-Ar-
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NO demonstrated significant anti-hypertensive effects on spontaneously 
hypertensive rats. These effects were almost the same as those exerted by the 
ACE-inhibitor captopril and equivalent to (or perhaps slightly better than) those 
shown by the equimolar doses of the reference AT1-antagonist losartan. 
Furthermore, in this work it has been demonstrated that Los-Ar-NO also showed 
significant pharmacological effects in the reversion of the left ventricle 
hypertrophy, typical of spontaneously hypertensive rats. Again, these anti-
hypertrophic effects were very similar to those exhibited by the reference 
compounds captopril and losartan. 
Finally, important, albeit preliminary, experimental data demonstrated that Los-
Ar-NO seems to possess additional pharmacological features, not shown (or 
poorly shown) by the respective “native” drug losartan. In particular, Los-Ar-NO 
exerted a significant cardio-protective activity against the myocardial injury 
induced by an ischaemia-reperfusion cycle. Furthermore, compound Los-Ar-NO 
was more effective than losartan in the reduction of the aggregating effect induced 
by ADP on rat platelets. These additional properties will be studied more in depth 
in future pharmacological investigations. 
Another essential future experimental approach will aim to the identification, 
among the various NO-sartans synthesised to date, of the one(s) exhibiting an 
optimal balance of the two pharmacodynamic mechanisms, i.e. the one(s) 
possessing the most convenient NO-releasing rate (Breschi et al., 2006) .  
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On the basis of our findings a chinese research group carried out the synthesis and 
the pharmacological characterization of a NO-releasing derivative of another 
AT1-antagonist such as telmisartan. The new hybrid drug, named WB1106, 
results composed by telmisartan as native molecule and a pyridinic linker bringing 
the nitrooxy group conjugated by an esteric bond between the carboxylic group of  
telmisartan and the linker hydroxylic group. 
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Figure 27. Molecular structure of the NO-releasing derivative of telmisartan WB1106. 
The same vasorelaxing protocol carried out for the originals NO-sartans indicates 
the WB1106 presents an efficay value similar to its Losartan-based analogue and 
a potency index almost in the micromolar range. Even for this compound has been 
evaluated the in vivo anti-hypertensive activity on SHR by the tail-cuff method 
using the native sartan and an ACE-inhibitor as reference drug and even WB1106 
like the pioneer Los-Ar-NO caused a lowering of systolic blood pressure values of 
SHR, leading these values near to the typical systolic blood pressure of a 
normotensive rat. Moreover, WB1106, in contrast to equimolar telmisartan, 
significantly attenuates body weight gains and improves glucose tolerance in 
high-fat and carbohydrate-fed rats (Li et al., 2007). These results obtained by 
another group confirm NO-sartans as new hybrid molecule in which the 
pharmacodynamic profile of the native drigs was preserved but even enriched 
with useful additional properties due to the NO-donor moiety. 
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CHAPTER 4 
 
 
 
 
NO-ANTI DIABETIC DRUGS* 
 
 
*The contents of chapter 4 have been already published: 
 
 
 
PATENT PI2006A000103 “Ibridi farmacodinamici con attività ipoglicemizzante 
e NO-donor ottenuti dalla coniugazione di derivati idrossilati della glibenclamide 
con acidi carbossilici nitrossi-sostituiti” Università di Pisa. 
 
 
 
 
 
 
                                                               NO-ANTI-DIABETIC DRUGS 
                                                                                 109
Introduction 
Diabetes mellitus is a multifactorial disease associated with a number of 
microvascular (retinopathy, neuropathy, and nephropathy) and macrovascular 
(ischeamic heart disease, cerebrovascular disease and peripheral vascular 
diseases) complications (Virsaladze and Kipiani, 2001; Cooper et al., 2001; Clark 
and Lee, 1995). During the development of diabetes several biochemical 
(oxidative stress, modified low-density lipoprotein cholesterol, impaired NO 
production and chronic inflammation) and mechanical (low shear stress and 
hypertension) factors converge against the endothelium, resulting in endothelial 
dysfunction and vascular inflammation. So all these harmful stimuli associated 
with, and derived from, the state of insulin resistence and type 2 diabetes 
markedly enhance endothelial dysfunction, which determines a NO reduced 
biosynthesis by endothelium providing the pathophysiological basis for a great 
cardiovascular risk (Hartge et al., 2007).  
On the basis of these remaks the exigency emerged to couple the hypoglicemic 
activity of an insulin secretagogue such as Glibenclamide, commonly employed 
in the type 2 diabetes therapy, with the several benefical properties of NO such us 
the vasorelaxing, anti-platelet/anti-thrombotic and cardioprotective activities. 
In order to obtain an hybrid molecule in which the NO-donor moiety is 
conjugated to the native drug by an in vivo easily hydrolizable bond such as the 
esteric one, Glibenclamide, as native drug, is replaced by one of the two its active 
metabolites, the 4-trans-hydroxyglibenclamide (Gli-OH) possesing a hydroxy 
group useful for the esteric bond. 
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In order to modulate the release of nitric oxide, two different NO-donor linkers 
bringing the nitrooxy group, respectively, in meta or in para position were 
synthesised and pharmacologically evaluated. 
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Figure 27. Molecular structures of the reference drugs such as Glibenclamide and 4-trans-
hydroxy-Glibenclamide and of the new hybrid compounds meta-NO-Glibenclamide and para-NO-
Glibenclamide. 
 
 
Glibenclamide 
4-trans-Hydroxy-Glibenclamide 
meta-NO-Glibenclamide 
para-NO-Glibenclamide 
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Chemistry 
From a chemical point of view, it is possible to summarise the synthesis of the 
two hybrid derivatives of hydroxy-Glibenclamide as a condensation reaction 
between a hydroxylated derivative of the suphonylurea (such as the active 
glibenclamide metabolite, hydroxylated on the cycloexylic ring) and a carboxylic 
acid.; this synthetic route  could be carried on according usual procedures, in the 
presence of dicyclohexylcarbodiimide (DCC) and catalytic amount of 
dimethylaminopyridine (DMAP), as reported in literature in R.A. Hill et al Bioorg 
Med Chem, 11, 2003, 2099-2113. 
 
 
 
 
 
 
The two nitrooxy-derivatives of the active metabolite of Glibenclamide (4-trans-
hydroxy-Glibenclamide = Gli-OH ), underwent an in vitro pharmacological 
study on animal models focused to demonstrate an additional vasorelaxing NO-
mediated effect conferred through the conjunction of NO-donor moiety. At the 
same time, these new hybrid molecules were evaluated by another in vitro 
experimental protocol on human pancreatic islets aimed to verify the preservation 
of the insulinotropic response. 
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Pharmacological procedures 
All the experimental procedures were carried out following the guidelines of the 
European Community Council Directive 86-609. 
 
In vitro protocols. 
The effects of the compounds were tested on isolated thoracic aortic rings of male 
normotensive Wistar rats (250-350 g). After a light ether anaesthesia, rats were 
sacrificed by cervical dislocation and bleeding. 
The aortae were immediately excised, freed of extraneous tissues and the 
endothelial layer was removed by gently rubbing the intimal surface of the vessels 
with a hypodermic needle. Five mm wide aortic rings were suspended, under a 
preload of 2 g, in 20 mL organ baths, containing Tyrode solution (composition of 
saline in mM: NaCl 136.8; KCl 2.95; CaCl2 1.80; MgSO4 1.05; NaH2PO4 0.41; 
NaHCO3 11.9; Glucose 5.5), thermostated at 37 °C and continuously gassed with 
a mixture of O2 (95%) and CO2 (5%). Changes in tension were recorded by means 
of an isometric transducer (Grass FTO3), connected with an  unirecord 
microdynamometer (Buxco Electronics). 
 
Evaluation of the NO-releasing properties 
After an equilibration period of 60 minutes, the endothelium removal was 
confirmed by the administration of acetylcholine (ACh) (10 μM) to  KCl (30 
mM)-precontracted vascular rings. A relaxation < 10% of the KCl-induced 
contraction was considered representative of an acceptable lack of the endothelial 
layer, while the organs, showing a relaxation ≥ 10% (i.e. significant presence of 
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the endothelium), were discarded. In the first series of experiments, we 
investigated the possible NO-releasing effect of the tested compounds. 
From 30 to 40 minutes after the confirmation of the endothelium removal, the 
aortic preparations were contracted by a single concentration of KCl (30 mM) and 
when the contraction reached a stable plateau, 3-fold increasing concentrations of 
meta-NO-Glibenclamide and para-NO-Glibenclamide (1nM-10μM) were 
added. 
Preliminary experiments showed that the KCl (30 mM)-induced contractions 
remained in a stable tonic state for at least 40 minutes. 
The same experiments were carried out in the presence of a well-known 
guanylate-cyclase inhibitor: ODQ 1μM which was incubated in aortic 
preparations after the endothelium removal confirmation. 
 
Time-course of NO-mediated vasorelaxing effect 
From 30 to 40 min after confirmation of endothelium removal, aortic preparations 
were contracted with a single concentration of KCl 30mM, and after a stable 
plateau had been reached, a single concentration (1μM) of the compounds or of 
the reference drug sodium nitroprusside (SNP)was added. The vasorelaxing effect 
of the added compounds was monitored for 50 min. 
 
Materials. 
Substances used in the experimental protocols were KCl (Carlo Erba) dissolved 
(3M) in Tyrode solution, acetylcholine chloride (Sigma) dissolved (0.1 M) in 
EtOH 95% and further diluted in bidistillated water. ODQ (Sigma) was dissolved 
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(1 mM) in EtOH 95% and further diluted in Tyrode solution. Compounds meta-
NO-Glibenclamide and para-NO-Glibenclamide were dissolved (10 mM) in 
DMSO and further diluted in Tyrode solution. 
All the solutions were freshly prepared immediately before the pharmacological 
experimental procedures. Previous experiments showed a complete 
ineffectiveness of the administration of the vehicles. 
 
Data analysis.  
The vasorelaxing efficacy was evaluated as maximal vasorelaxing response, 
expressed as a percentage (%) of the contractile tone induced by KCl 30 mM. 
When the limit concentration 10 μM (the highest concentration, which could be 
administered) of the tested compounds did not reach the maximal effect, the 
parameter of efficacy represented the vasorelaxing response, expressed as a 
percentage (%) of the contractile tone induced by KCl 30 mM, evoked by this 
limit concentration. The parameter of potency was expressed as pIC50, calculated 
as negative logarithm of the molar concentration of the tested compounds evoking 
a half reduction of  the contractile tone induced by KCl 30 mM. The pIC50 could 
not be calculated for those compounds showing an efficacy parameter lower than 
50%.  The parameters of efficacy and potency were expressed as mean ± standard 
error, for 5-10 experiments. Student t test was selected as statistical analysis, P < 
0.05 was considered representative of significant statistical differences. 
Experimental data were analysed by a computer fitting procedure (software: 
GraphPad Prism 4.0). 
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Functional evaluation of Gli-OH and para-NO-Glibenclamide on human 
pacreatic islets. 
Pancreatic islets were isolated by collagenasic digestion of the gland and 
following purification on density gradient. 
Pancreas was freed of extraneous tissues and some portions were selected 
(generally the body and the tail of the gland). For the digestion the collagenase 
enzyme (collagenase P, Roche) was employed.  Pancreatic duct was incannulated 
and the digestion solution (collagenase 1,5 mg/ml, dissolved in 200ml of Hanks’ 
Balanced Salts=HBSS) additionated with 2% of human albumin, (Human-
Albumin® Biagini 20% ), was slowly injected to distend the tissue. After the 
distension, pancreatic gland was introducted in a 800ml glass becker and placed in 
a thermostated bath at 36,5 °C.  The action of collagenase was checked after 8 
minutes for the first time and then every 3 minutes observing a sample of the 
gland on a inverted light microscope. After about 15 minutes, the becker was 
removed from the thermostated bath and pancreas was continuosly stirring by 
sterile surgical pliers as long as the digestion was complete. Then the tissue was 
filtered through steel sieves ordinated according the pore width, first 400 and then 
90 μm. The tissue keeped on the 400 μm filter was recuperated to continue the 
digestion. The tissue keeped on the 90 μm filter was recuperated  with HBSS 
additionated with 2% of human albumine in a 2000 ml becker. The same 
filtration, washing and storing in HBSS solution was repeated every 5 minutes for 
45 minutes or to complete organ digestion. 
The purification procedure targeted the separation of the exocrine tissue from the 
endocrine one. The HBSS volume collected was divided in conic polypropilene 
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50 ml tubes and centrifuged at 250g for 2minues at 4 °C. The top layer was 
discared and the pellet (about 1-2 ml) was resuspended with 15 ml of a solution 
composed by 80% Lymphoprep (Nycomed) and 20% HBSS.  On the surface of 
the solution 10 ml of Hanks’s were placed in order to obtain the convenient 
garadient of density. After centrifugation at 909g for 5 minutes at 4 °C, the islets 
were concentrated on the interface between the Lymphoprep layer and the HBSS 
one where they were recuperated and again centrifuged at 909g for 2 minutes at 
4°C. At the end of the procedure, shares containing about 2500 islets were 
suspended in 40ml of colture medium (M199 additionated with 10% of bovine 
serum and antibiotics), placed in plastic flasks for suspeded cell coltures (75 cm2, 
Iwaki) and placed in an incubator at 27°C and 5% CO2.  The medium was 
replaced for the first time the morning following the isolation in order to slow 
down, by dilution, the collagenase action, then was replaced weekly to renew the 
essential colture components (Bugliani et al., 2004). 
To determine in vitro the functionality of β-cells, the isolated islets undewent a 
static incubation in Krebs-Ringer-bicarbonate-Hepes solutions (KRBH), 
additionated with 0,5% of albumin and Glucos at the concentration of 3,3 mM and 
16,7 mM a pH 7,4. Groups of islets having similar size were placed into 5 ml 
polypropilene tubes and pre incubated for 45 min with KRBH solution containing 
glucose 3,3, mM. From every tubes a share of top layer was collected in order to 
determine the amount of released insulin in basal conditions. Subsequently the 
same islets were incubated for 45 minutes with glucose 16.7 mM or with 
Glibenclamide 10 μM and 100 μM, or with the its metabolite 4-trans–hydroxy-
Glibenclamide 10 μM and 100 μM, or with the new hybrid drug para-NO-
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Glibenclamide 10 μM and 100 μM. Then from every tube a top layer share was 
collected in oder to determine the amount of released insulin following the 
stimulus. The isulinaemia determination was performed with IRMA method (Lupi 
et al., 2002; Marchetti et al., 2002).   
IRMA method is an immunoradiometric assay based on the employment of 
antibodies, radioactively labelled, directed versus the antigene which must be 
determined. For this assay polypropilene tubes with a special bottom covered with 
monoclonal antibodies anti-insulin were employed. After the addition of the 
sample, a monoclonal antibodies, labelled with with I125 was added. After 
washing, the remaining radioactivity linked to the tube represented the antigene 
concentration. The dosage kit used for this assay was the Insulin-IRMA 
(PANTEC srl) (Lupi et al., 2002; Wilson and Walker, 1995). 
The described procedures were carried out in two days: 
1st Day: The day before the experiment, the samples were placed at 4 °C. 
2nd Day: The kit standards was prepared through the addition of fixed volumes of 
milliQ water and mixed with the vortex. In numbered tubes was introducted 50μl 
of standards or of the samples. Subsequently in every tube were added  50μl of 
radioactive antibody and after mixing the sample were incubated for two hours at 
room temperature. At the end of the incubation 1 ml of washing buffer was added. 
Then the buffer was sucked up through a vacuum pomp and the washing 
procedures was twice repeated. Every sample of the numerically raising sequence 
was analysed by a γ-meter for 60 seconds. The standard curve graph was analysed 
by the software: this graph reported on Y axis the number of shot for minute and 
on the X axis the concentration of the related standard sample. 
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Results 
The reference drugs Glibenclamide and 4-trans-Hydroxy-Glibenclamide (Gli-
OH), were devoid of any significant vasorelaxing effect. On the other hand,  
the two hybrid compounds, meta-NO-Glibenclamide and para-NO-
Glibenclamide caused concentration dependent vasorelaxing response (pIC50= 
5.64 ± 0.05 and pIC50= 6.75 ± 0.12, respectively) which were antagonised by 
ODQ 1μM, indicating that the activity was really due to the release of NO (Figure 
29). 
 
 
 
 
 
 
 
 
 
 
  
Figure 29. Concentration-vasorelaxing effect curves of selected compounds. X Axis : Logarithm 
of the molar concentration of the tested compound; Y Axis: vasorelaxing effect, expressed as a 
percentage (%) of the contractile tone induced by KCl 30 mM; Bars: standard errors. 
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Consistently with the pIC50 values recorded with the cumulative concentration-
response curves, the results emerging from the time-course protocol showed that, 
as already demostrated in the NO-sartans a and in the linkers time course curve, 
the NO-releasing rate exhibited by the hybrid that brings the NO-releasing moiety 
in the para position is higher than that exhibited by the hybrid in which the NO-
donor moiety is in meta position. 
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Figure 30. Time course profile of the vasorelaxing effect evoked by the concentration 1μM of the 
NO-anti-diabetic hybrids. X Axis: time expressed in minutes. Y Axis: vasorelaxing effect, 
expressed as a percentage (%) of the contractile tone induced by KCl 30 mM; Bars: standard 
errors. 
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As concerns the evaluation of the insulinotropic effects, human islets were 
isolated by collagenase digestion and density gradient purification from the 
pancreas of 4 multiorgan donors:  
Age (years):  61 ± 15; 
Gender (M/F):  3/8  
BMI (body mass index  25.0±4.1 Kg/m2).  
Glibenclamide was choosen as reference drug.  
Insulin release at basal glucose (3.3 mM) was 41.0±22.3 µU/ml.  
The parameters of stimulation index are shown in Fig. 31 and Tab.6 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Insulin secretion was studied in response to high glucose (16.7 mM), Glibenclamide 
(10 and 100 µM), 4-trans-Hydroxy-Glibenclamide (Gli-OH) (10 and 100 µM) and one of the 
two new hybrid compounds: para-NO-Glibenclamide (10 and 100 µM). On the Y Axis the 
insulinotropic activity was expressed as Stimulation Index (S.I. = ratio between the insulin release 
in response to a tested compound and the basal release). 
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Compound 
Stimulation 
Index (SI) 
█   Glucose 16.7 mM 4.9 ± 0.7 
█   Glibenclamide 10 μM 4.3 ± 0.9 
█   Gli-OH 10 μM 6.0 ± 0.9 
█   para-NO-Gli 10 μM 6.3 ± 0.8 
█   Glibenclamide 100 μM 5.2 ± 0.9 
█   Gli-OH 100 μM 8.2 ± 0.9 
█   para-NO-Gli 100 μM 8.3 ± 0.8 
 
Table 6. Stimulation Indexes (S.I. = ratio between the insulin release in response to a tested 
compound and the basal release) of the tested compounds. 
 
These preliminary studies showed that Gli-OH and para-NO-Glibenclamide 
possess, on human islets, insulinotropic effects comparable to that exhibited by 
Glibenclamide (See Table 6). Furthermore, meta-NO-Glibenclamide and  para-
NO-Glibenclamide showed NO releasing properties, which can be considered as 
a complementary pharmacodynamic feature, of potential usefulness for 
cardiovascular complications associated with the diabetic status such as 
endothelial dysfunction (PATENT PI2006A000103). 
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Discussion 
As reported in literature, besides the known alteration on metabolism, the diabetic 
pathology leeds to several cardiovascular implications (such as micro and 
macrovascular complications, ischaemic heart disease) deriving from endothelial 
dysfuction, a pathological condition in which the disruption of vessel endothelium 
lees to a lack of several endothelial factors, and above all of nitric oxide with a lot 
of consequences on cardio-vascular system. In order to approach a multifactorial 
pathology such as type II diabetes, often the therapy of diabetic patients is 
composed by several drugs as associations of more hypoglycaemic different 
molecules additioned by anti-hypertensive and anti-ischaemic drugs. Moreover 
recent studies highlight that if the correction of glycaemia by hypoglycaemic 
drugs could leeds to an improvement of cardiovascular diseases associated with 
diabetes type II, this observation could not be applicated to some sulphonylureas,  
as a consequence of their mechanism of action on KATP potassium channels. In 
fact Glibenclamide acts as a secretagogue of insulin blocking the KATP 
potassium channel, so allowing the increasing of calcium concentration needed 
for the insulin release. But on the contrary the opening of KATP channel, at 
cardiac level, seems to be responsible for the pre-conditioning “phenomenon” that 
results in a cardioprotective mechanism. 
So according with the “Hybrid philosophy”, that is : correction of adverse effects 
and improvement of the native pharmacodynamic profile, this new class of NO-
releasing hypoglycaemic drugs seems to goal the target. 
Infact the obtained results showed that the introduction of the NO-donor moiety 
results in a real source of exogenous NO, probably following an enzymatic 
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mechanism, typical of nitric esters. This assumption derives from the 
experimental evidence on the vascular smooth muscle where the hybrids moleculs 
evoked a vasorelaxing response inhibited by the block of cGMP pathway by 
ODQ. 
As observed for NO-Sartans a tuning of the NO-donor activity seems to be 
important for a correct balancing between the two pharmacodynamic properties 
and with this target, two different hybrid with diffent NO-releasing properties 
have been synthesised. The meta-NO-Glibenclamide exhibited a lower releasing 
rate emerging from a lower potency value and a slower time-course; consistently 
with the NO-sartans series the para-NO-Glibenclamide showed potency indexes 
higher then the meta-hybrid and a time course curve that indicates a quicker NO-
releasing rate. Further in vivo studies will  identify the hybrid with the optimum 
balancing. Once confirmed the addition of new cardiovascular properties due to 
the insertion of the NO-donor moiety, the study was aimed to confirm the 
preservation , despite of the structural modification, of the native hypoglycaemic 
property. The in vitro study on human pancreatic islets demonstrated that, as 
reported in literature, the active metabolite of Glibenclamide, Gli-OH maintains 
the insulin secretagogue property and that this activity was confirmed even for the 
hybrid para-NO-Glibenclamide.  
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